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Loss of E-cadherin (Cdh1), Smad4 and p53 have all been shown 
to play important roles in gastric cancer formation. Compound 
conditional knockout mice for Smad4, p53, and E-cadherin were 
generated to further define and compare the roles of these genes in 
gastric, intestinal and breast cancer development by crossing them 
with Pdx-1-Cre, Villin-Cre and MMTV-Cre  transgenic mice. We 
have determined that gastric adenocarcinoma was more frequent in 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice than in Pdx-1-




Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice developed gastric 
adenocarcinomas without E-cadherin expression. However, 
intestinal and mammary adenocarcinomas with the same genetic 
background retained the E-cadherin expression and were 
phenotypically similar to mice with both wild-type Cdh1 alleles. 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice developed gastric 
adenocarcinomas more rapidly than Pdx-1-Cre;F/F;Trp53 
F/F;Cdh1F/F mice, demonstrating that Cdh1 heterozygosity 
accelerates the development and progression of gastric cancer, in 
combination with loss of Smad4 and p53. Lung metastases were 
identified in 14.2% Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, but 
not in the other genotypes. Nuclear β-catenin accumulation was 
identified at the invasive tumor front of gastric adenocarcinomas 
arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. This 
phenotype was less prominent in mice with intact E-cadherin or 
Smad4, indicating that the inhibition of β-catenin signaling by E-
cadherin or Smad4 may down-regulate signaling pathways involved 
in metastases in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. 
Knockdown of β-catenin significantly inhibited migratory activity 
of Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cell lines. Thus, loss of 
E-cadherin and Smad4 cooperate with p53 loss to promote the 
development and metastatic progression of gastric adenocarcinomas, 
with similarities to human diffuse-type gastric cancer.  
Furthermore, a primary cell line, designated NCC-S1 was 




Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse to establish a metastatic 
gastric cancer model. A cancer subpopulation of NCC-S1 cells was 
isolated from lung metastases that developed from heterotopic 
tumors transplanted into severe combined immunodeficiency mice. 
The metastasis derived cells, designated NCC-S1M, formed 
orthotopic tumors and exhibited a significant improvement in in vivo 
metastatic potential compared with the parental cell line, showing 
epithelial to mesenchymal transition (EMT) features.  NCC-S1M 
cells demonstrated many features of cancer stem cells, including 
the ability to initiate tumor formation and chemoresistance. 
Importantly, Sca-1 was found to be over-expressed in NCC-S1M 
cells than NCC-S1 cells. Sca-1 positive cells demonstrated 
increased ability to initiate tumor formation and in vivo 
chemoresistance than Sca-1 negative cells, showing up-regulation 
of interleukin 1 signaling pathway. Over-expressed genes in Sca-1 
positive NCC-S1 cells clustered in 123 metastatic gastric cancer 
patients according to overall survival following cisplatin/fluorouracil 
chemotherapy. Taken together, we have identified Sca-1 as a 
murine gastric cancer stem cell marker using this unique metastatic 
cell line models. 
---------------------------------------- 
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Gastric cancer is the second most common cause of cancer death 
worldwide (Alberts, Cervantes et al. 2003). According to Lauren’s 
histological classification, gastric cancer can be subdivided into two 
main histological subtypes: diffuse and intestinal (Lauren 1965). 
Intestinal-type gastric cancer is the most common variant at high 
risk and is composed of gland-like structures that mimic the 
glandular architecture of the intestinal mucosa. Intestinal gastric 
cancer is recognized by a series of premalignant lesions such as 
atrophy, intestinal metaplasia, and dysplasia. Diffuse-type gastric 
cancer is relatively less frequent than intestinal-type and lacks the 
formation of glandular structure. Unlike intestinal-type gastric 
cancer, diffuse gastric cancer usually arises in the context of  
chronic inflammation without any identifiable histological precursor 
lesions (Correa and Shiao 1994). Environmental factors, such as 
diet and Helicobacter pylori (H. pylori) infection, strongly influence 
the development and progression of intestinal-type gastric cancer, 
whereas the role of genetic influences is more important than 
environmental factors in diffuse-type gastric cancer. 
p53, Smad4, and E-cadherin are frequently inactivated in human 
gastric cancer. TP53 mutations are reported in 0%-21% of 




respectively (Maesawa, Tamura et al. 1995). Smad4, a co-Smad 
involved in both branches of the TGF-β/BMP signaling system 
(Schmierer and Hill 2007), is inactivated in 40% of human gastric 
cancers by loss of heterozygosity (LOH),  promoter 
hypermethylation, and somatic mutation (Wang, Kim et al. 2007). 
The CDH1 gene, coding for E-cadherin, is frequently inactivated in 
familial and sporadic diffuse-type gastric cancers (Becker, 
Atkinson et al. 1994). Although the inactivation of these genes has 
been implicated in gastric carcinogenesis and the need for research 
in this field is undisputed, a murine gastric cancer model for the 
systemic evaluation of the effects of these genes in gastric 
development and progression is lacking. 
 To explore gastric carcinogenesis, genetically engineered mouse 
models, particularly in knockout mice, have been used because 
these models have considerablely contributed to understanding the 
pathways and mechanisms underlying gastric carcinogenesis. There 
are only a few murine gastric cancer cell lines available in the 
scientific community, but not of them are genetically defined since 
the tumors were carcinogen-induced. Several genetically 
engineered mouse models for gastric cancer have been reported, 
but they have been generated using K14 and Atb6 promoters.  
These models have been generated in the lineage of parietal cells 
(Wang, Dangler et al. 2000; Oshima, Matsunaga et al. 2006; 




ever originate. Thus, in the scientific and pharmaceutical 
communities, there is a need for genetically defined, murine gastric 
cancer cell models that closely recapitulate human gastric cancer to 
facilitate a comprehensive understanding of the mechanisms 








E-cadherin in cancer 
E-cadherin, encoded by the CDH1 gene, is a tumor suppressor 
protein prominently associated with tumor development, tumor 
invasion, metastasis, and poor patient prognosis (Schipper, Frixen 
et al. 1991; Oka, Shiozaki et al. 1993; Umbas, Isaacs et al. 1994). 
E-cadherin is a single-span transmembrane that forms the core of 
the epithelial adherens junction by establishing a homophilic 
interaction with the adjacent E-cadherin of neighboring cells 
(Nagafuchi, Shirayoshi et al. 1987; Gumbiner 2005). It is well 
known that the loss E-cadherin-mediated cell-to-cell adhesion is 
a prerequisite for tumor development, invasion and metastasis 
(Birchmeier and Behrens 1994).  
Other than its structural role in stabilizing cell-to-cell contact, 
E-cadherin/β-catenin complex in its intracellular region serves an 
important role in activating the Wnt signaling pathway (Tian, Liu et 
al. 2011). Disrupting this complex by loss of E-cadherin increases 
the amount of stabilized cytoplasmic β- catenin, which then 
translocates to the nucleus and functions as an activator for T-cell 
factor (TCF)/lymphoid enhancer factor (LEF) (Fig 1). The 
activated Wnt signaling pathway subsequently modulates the 
expression of TCF/LEF1 target genes, including the proto-
oncogene c-Myc and cyclin D1. 
The mechanisms of E-cadherin inactivation include gene 




translational modification and transcriptional repression (Guilford, 
Hopkins et al. 1998; Hirohashi 1998; Rashid, Sanda et al. 2001). E-
cadherin is frequently inactivated in familial and sporadic diffuse-
type gastric cancers (Becker, Atkinson et al. 1994). Germline 
CDH1 mutations are associated with an 80% lifetime risk of 
diffuse-type gastric cancer, and somatic inactivating E-cadherin 
mutations have been reported in 33%-50% of sporadic diffuse-
type gastric cancers (Becker, Atkinson et al. 1994). Promoter 
hypermethylation of CDH1, identified in up to 80% of patients with 
diffuse-type gastric cancers, is the most common second hit in the 
inactivation of the wild type CDH1 allele, but mechanisms leading to 
the inactivation of the wild type CDH1 allele remain largely 
unknown (Machado, Oliveira et al. 2001; Rosivatz, Becker et al. 
2002). A better understanding of the stepwise inactivation of E-
cadherin would provide an opportunity for therapeutic intervention 













Fig 1. E-cadherin/β- catenin complex in epithelial cell-cell 




Smad4 and p53 in gastric cancer 
Smad proteins are the critical components of the transforming 
growth factor-β (TGF-β) signaling pathway that regulate many 
cellular functions including cell growth, adhesion, migration, cell-
fate determination and differentiation, and apoptosis (Schmierer 
and Hill 2007). Smad4 is a co-Smad involved in both branches of 
the TGF-β/BMP signaling system (Fig 2). Complex formation of 
the phosphorylated receptor-regulated SMADs with SMAD4 
translocated to the nucleus and the nuclear accumulation of active 
SMAD complexes directly regulate gene transcription in 
conjunction with transcription factors.  
During initiation and early progression of the tumor, TGF-β/BMP 
signaling serves as a tumor suppressor by inhibiting proliferation 
and accelerating apoptosis, which is supported by various in vitro 
and in vivo studies via either cell-autonomous or non-cell 
autonomous mechanisms and loss or mutation of the members of 
the TGF-β/BMP signaling pathway in human cancer (Dhawan, 
Singh et al. 2005; Yang and Yang 2010). Alteration of Smad4 gene 
is frequently observed in gastrointestinal tumors such as familial 
juvenile polyposis, an autosomal dominant disease characterized by 
predisposition to gastrointestinal polyps and cancer (Miyaki and 
Kuroki 2003). Smad4 is inactivated in 40% of human gastric 
cancers by loss of heterozygosity (LOH), promoter 




Oncogenic roles in tumorigenesis have been investigated in human 
cancer. In the late stage of tumor progression, upregulated TGF-
β/BMP signaling might promote tumor cell migration, invasion, and 
angiogenesis with being associated with poor prognosis for cancer 
patients (Elliott and Blobe 2005). However, the dual roles of 
TGF-β/BMP signaling in cancer is both cell-specific and 
context-dependent. Therefore, there is an urgent need to evaluate 
the roles of TGF-β/BMP signaling in gastric carcinogenesis and 
establish crosstalk communication with other pathways. 
p53 plays a critical role in maintaining the genetic intergrity of 
proliferating cells, thereby making it renowned as the “Guardian of 
the Genome”(Lane 1992). In its wild-type form, p53 is a major 
tumor suppressor whose function is critical for protection against 
cancer. In addition, inactivation of the protein is a frequent event in 
tumorigenesis (Rivlin, Brosh et al. 2011). It is well established that 
p53 inactivation and mutant p53 expression can grant cells with 
additive growth and survival advantages, such as increased 
proliferation, evasion of apoptosis, and chemoresistance (Sigal and 
Rotter 2000; Brosh and Rotter 2009). TP53 mutations are reported 
in 0%-21% of diffuse-type and 36%-43% of intestinal-type 
gastric cancers, respectively (Maesawa, Tamura et al. 1995).  
Under normal conditions, both Sma4 and p53 act as gene-specific 
transcription factors to regulate various genes producing tumor 




proteins, the convergence of p53 and Smad4 signaling pathways 
have been investigated in several studies. However, the 
convergence of these proteins has not been demonstrated in gastric 
carcinogenesis. A systemic evaluation of the effects of these 
proteins in gastric development and progression in gastric cancer is 
required to facilitate a comprehensive understanding of the 
mechanisms underlying the function of Smad4 signaling and p53 in 







Fig 2. Core signaling in the mammalian TGF-β/BMP signaling -




Gastric cancer stem cell 
It is postulated that tumors are composed of heterogeneous cancer 
cells and that only a rare subpopulation of cells known as cancer 
stem cells (CSC) are responsible for sustaining tumorigenesis and 
establishing the heterogeneity inherent in tumors (Visvader and 
Lindeman 2012). Tumors may originate from the CSCs that are able 
to maintain tumor growth, tumor recurrence, apoptosis, and 
chemoresistance (Visvader and Lindeman 2012). Thus, CSCs 
promise the development of anticancer drugs. They exhibit 
characteristics that are similar to normal stem cells such as 
unlimited self-renewal and multi-lineage differentiation. Despite 
many uncertainties about the existence of CSCs, recent in vivo 
experiments suggest that tumors originate from CSCs (Driessens, 
Beck et al. 2012; Schepers, Snippert et al. 2012).    
 The first prospective identification of CSCs was made by Dick et al 
for acute myeloid leukemia(AML), subsequently demonstrating 
their existence in diver solid tumors (Visvader and Lindeman 2008). 
Putative CSCs are usually identified based on the expression of 
specific cell surface markers. Recently, gastric CSCs have been 
proposed in many gastric cancer cell lines and primary tumors using 
several candidate cell surface markers (Table 1). Lineage tracing 
studies have shown that Lgr5+ cells are multipotent stem cells 
responsible for the long-term renewal of the entire gastric 




rapidly formed tumors in the pylori epithelium in animal models 
(Barker and Clevers 2010). However, Lgr5 has been described as 
being expressed in both tumorigenic and non-tumorigenic cells 
(Takaishi, Okumura et al. 2009). Among the numerous surface 
markers currently under investigation, CD44 have proven to be the 
most useful for the identification of CSCs in gastric cancers 
(Takaishi, Okumura et al. 2009). Using the flow cytometry cell 
sorting method, Takaishi et al. isolated CD44+ cells from a panel of 
human gastric cancer cell lines, which formed spheroid colonies 
under non-adherent conditions in serum-free media and xenograft 
tumors in immunodeficient mice. CD44+ cells showed the 
properties of self-renewal and formed differentiated progeny of 
CD44- cells. 
The rapidly evolving field of CSC research has generated great 
interest in its therapeutic application in gastric cancer. Over the last 
few years, using lineage tracing and molecular marker labeling, 
several gastric CSC populations have been defined and have shown 
that heterogeneity exists in gastric cancer, which suggests that we 
need to use a combination of these markers to target different 
populations of gastric CSCs. Therefore, further investigation is 
required to evaluate CSC phenotypes using different markers, 
different experimental approaches, and gene expression signatures 
to lead to a greater understanding of gastric CSC pathways and 




Table 1. Summary of putative gastric stem/progenitor cells and 
cancer stem cell markers (Singh 2013) 
Markers 
Location and function 
Normal stomach Gastric cancer 
Lgr5 Base of pyloric gland, give 
rise to all cell types (lineage 
tracing) 
Luminal surface, tumor 
centre and invasion front 
(Immunostaining, 100 GC 
patients analyzed) 
 
TFF2 Isthmus region of corpus, 
gland base (mRNA 
expression) in mice, give rise 
to neck, chief and parietal 
cells only (lineage tracing) 
Expressed in SPEM following 
DMP-777 treatment, due to 
trans-differentiation of chief 
cells 
 Progressive loss of 
expression in H. pylori-
positive gastritis, IM and GC 
in human and mice 
 
DCKL1/DCAMKL1 Isthmus region of corpus 
(immunostaining) 
Expression expanded in 
murine models of acute 
gastritis, chronic ulcer and in 
Kras environment 
   
Sox2 1 and 2 cells above the base 
of corpus and antrum in mice 
stomach, give rise to cells in 
both the corpus and pylorus 
(lineage tracing) 
Expression associated with 
invasion and lymph node 
metastasis in GC 
(Immunostaining, 290 GC 
patients analyzed) 
 
Sox9 Weak expression in 
neck/isthmus of corpus, 
moderate expression in 
neck/isthmus of pylorus 
(immunostaining) 
Strong expression observed 
in GC (46 patients analyzed 
by immunostaining) 
 
Bmi-1 Weak to moderate expression 
in pits and isthmus of corpus 
and neck region of antrum 
Strong expression in GC 
(immunostaining) 
 
Oct4 Isthmus region of pit gland, 
pyloric antrum of human 
stomach (immunostaining) 





CD44 Strong expression in lower 
glandular cells of the gastric 
antrum and rare expression in 
corpus 
Strong expression GC 
(isolated cells from cancer 
cell lines and mouse and 
human gastric samples 
produce spheroid colonies, 
and show tumorigenicity) 
 
CD71-cell n/t Show higher tumorigenicity 
and multipotency, highly 
invasive and to exist in the 
invasive fronts of cancer foci 
   
CD133 Base of gastric glands, antrum Strong expression in GC, 
expressed on the luminal 
surface membrane of gland-
forming cells (patient 
samples) 
 
EpCAM+/CD44+ n/t Isolated cells produce 
spheroid colonies, and show 
tumorigenicity 
   
CD44+CD24+ n/t Isolated cells from gastric 
tissues of patients produce 
spheroid colonies, and show 
tumorigenicity 
 
CD44+CD54+ n/t Isolated cells from human 
gastric tumor tissues and 
peripheral blood of patients 
produce spheroid colonies, 
and show tumorigenicity 
 
CD90 n/t Isolated cells from gastric 
primary tumors produce 
spheroid colonies, and show 
tumorigenicity 







p53, Smad4, and E-cadherin are frequently inactivated in human 
gastric cancer. However, the functional roles of these genes in 
gastric cancer development and progression have not been fully 
evaluated using in vivo models. We generated compound conditional 
knockout mice for Smad4, p53, and E-cadherin to define and 
compare the roles of these genes in gastric, intestinal and breast 
cancer development by crossing them with Pdx-1-Cre, Villin-Cre 
and MMTV-Cre transgenic mice. Moreover, we established the 
murine gastric cancer cell line model which was useful for testing 
immunotherapeutics and, possibly, anti-metastasis agents. Using 
this novel mouse gastric cancer cell line model, we tried to identify 
candidate murine gastric cancer stem cell markers and demonstrate 














LOSS OF E-CADHERIN AND SMAD4 COOPERATE TO PROMOTE 







Loss of E-cadherin (Cdh1), Smad4 and p53 have all been shown 
to play important roles in gastric, intestinal and breast cancer 
formation. Compound conditional knockout mice for Smad4, p53, and 
E-cadherin were generated to further define and compare the roles 
of these genes in gastric, intestinal and breast cancer development 
by crossing with Pdx-1-Cre, Villin-Cre and MMTV-Cre 
transgenic mice. We have determined that gastric adenocarcinoma 
was more frequent in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice 
than in Pdx-1-Cre;Smad4F/F;Trp53F/F mice [P<0.001]. Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice developed gastric 
adenocarcinomas without E-cadherin expression. However, 
intestinal and mammary adenocarcinomas with the same genetic 
background retained the E-cadherin expression and were 
phenotypically similar to mice with both wild-type Cdh1 alleles. 
Early onset human gastric cancer with CDH1 germline mutation 
demonstrated very low level of E-cadherin. Promoter 
hypermethylation of the CDH1 gene was not identified in the gastric 
cancer as in our mutant mice. Thus, loss of E-cadherin and Smad4 
cooperate with p53 loss to promote the development of gastric 
adenocarcinomas, with similarities to human diffuse-type gastric 





p53, Smad4, and E-cadherin are frequently inactivated in human 
gastric cancer. TP53 mutations are reported in 0% to 21% of 
diffuse- and 36% to 43% of intestinal-type gastric cancers, 
respectively (Maesawa, Tamura et al. 1995). Smad4, a co-Smad 
involved in both branches of the TGF-β/BMP signaling system 
(Schmierer and Hill 2007), is inactivated in 40% of human gastric 
cancers by loss of heterozygosity (LOH), promoter 
hypermethylation, and somatic mutation (Wang, Kim et al. 2007). 
The CDH1 gene, coding for E-cadherin, is frequently inactivated in 
familial and sporadic diffuse-type gastric cancers (Becker, 
Atkinson et al. 1994). Germline CDH1 mutations are associated 
with an 80% lifetime risk of diffuse-type gastric cancer, and 
somatic inactivating E-cadherin mutations have been reported in 
33-50% of sporadic diffuse-type gastric cancers (Becker, 
Atkinson et al. 1994). Promoter hypermethylation of CDH1, 
identified in up to 80% of patients with diffuse-type gastric cancers, 
is the most common second hit in the inactivation of wild type CDH1 
allele, but mechanisms leading to the inactivation of the wild type 
CDH1 allele remain largely unknown (Machado, Oliveira et al. 2001; 
Rosivatz, Becker et al. 2002). A better understanding of the 
stepwise inactivation of E-cadherin would provide an opportunity 
for therapeutic intervention. 




have been obtained through studies of genetically engineered mouse 
models. Knockout of Smad4 in the germline of mice results in 
embryonic lethality (Sirard, de la Pompa et al. 1998), whereas mice 
heterozygous for mutant Smad4 in the germline develop in situ 
gastric carcinomas after 18 month of age (Xu, Brodie et al. 2000). It 
still remains to be elucidated how the loss of Smad4 in gastric 
epithelium, alone and in combination with other tumor suppressors, 
promotes the progression of gastric cancers.  
While it was recently reported that Atb4-driven p53 and E-
cadherin knockout mice develop diffuse-type gastric cancers 
(Shimada, Mimata et al. 2012), the impact of E-cadherin 
heterozygosity on the development and progression of gastric 
cancer has not been previously evaluated. Based on human mutation 
profiles and prior studies, we assessed the role of one allelic loss of 
E-cadherin, alone or in combination with the loss of Smad4 and p53, 
on the development of diffuse-type gastric adenocarcinomas in 
mice. Additionally, we compared this gastric cancer model with 






Materials and Methods 
 
Mice 
Mouse studies were conducted with the approval of the Animal Care 
and Use Committees of National Cancer Center of Korea (NCC-
12-050E) and the National Cancer Institute (Bethesda, MD). Pdx-
1-Cre mice (B6.FVB-Tg(Ipf1-cre)1Tuv), originally generated by 
Dr. Lowy (Hingorani, Petricoin et al. 2003), were provided through 
the Mouse Models of Human Cancers Consortium (MMHCC) 
repository at the NCI Frederick Cancer Research Center. B6.Cg-
Tg(Vil-Cre)20Sy, FVB/N-Tg(MMTV-Cre)7Mul, and FVB.129-
Trp53tm1Brn (Jonkers, Meuwissen et al. 2001) mice were also 
provided by the MMHCC. B6.129-Cdh1tm2Kem/J mice, which have 
loxP sites flanking exons 6-10, were purchased from The Jackson 
Laboratory (Boussadia, Kutsch et al. 2002). Conditional Smad4 
knockout mice (Smad4F/F) on the Black Swiss, B6 and 129 
backgrounds were previously described (Yang, Li et al. 2002).  
Compound conditional knockouts of Smad4, p53, and E-cadherin 
were bred with Pdx-1-Cre mice, Villin-Cre mice, and MMTV-Cre 
mice, to perform targeted deletion for these genes in gastric, 
intestinal, and mammary epithelium, respectively. Pdx-1-Cre mice 
express Cre in mucosal epithelial cells of the gastric antrum and 
duodenum as well as the pancreatic islet cells (Larsson, Madsen et 




intestinal epithelial mucosa (el Marjou, Janssen et al. 2004) and of 
the antrum (Qiao, Ziel et al. 2007). MMTV-Cre mice expressed 
Cre in mammary epithelial cells and striated ductal cells of the 
salivary gland (Andrechek, Hardy et al. 2000). The strain 
background for crosses was controlled in order to avoid 
confounding variables of strain background in order to compare 
tumor-free survival across the genotypes. Offspring mice were 
genotyped using polymerase chain reaction (PCR) assays for tail 
DNA. PCR genotyping primers for Cdh1 were F: 5'-
CTTATACCGCTCGAGAGCCGGA-3' and R: 5'-
GTGTCCCTCCAAATCCGATA-3'. Amplicons of 900 and 980 bp 
were expected for wild-type and floxed alleles, respectively. PCR 
genotyping primers for Trp53 were F: 5'-
TGGAGATATGGCTTGGAGTAG-3' and R: 5'-
CAACTTACTTCGAGGCTTGTC-3'. PCR products of 420 and 500 
bp were expected for wild-type and floxed alleles, respectively. 
PCR genotyping primers for Smad4 were F: 5'-
GGGCAGCGTAGCATATAAGA-3' and R: 5'-
GACCCAAACGTCACCTTCAC-3'. PCR products of 390 and 480 bp 
were expected for wild-type and floxed alleles, respectively. 
Primers for Pdx1-Cre were F: 5'-
CTGGACTACATCTTGAGTTGC-3' and R: 5'-
CAGATTACGTATATCCTGGCAG-3’. Primers for Villin-Cre 




CAGATTACGTATATCCTGGCAG-3'. Primers for MMTV-Cre 




Mice positive for Pdx-1-Cre or Villin-Cre genes were monitored 
until they became moribund or showed signs of distress, at which 
time necropsies were performed. Scheduled sacrifice was also 
conducted for sentinel mutant mice without signs of distress, in 
order to evaluate the presence or absence of asymptomatic 
microscopic disease in stomach. MMTV-Cre positive female mice 
were euthanized when mammary tumors reached 2 cm in diameter. 
Carcinoma-free intervals were compared by log-rank test. When 
no carcinomatous lesions were identified in a given organ, it was 
censored for the development of carcinoma on the day of necropsy 
(Leung, Elashoff et al. 1997). Liver, spleen, and lung were 
harvested at necropsy to assess for metastases. 
For necropsy of Pdx-1-Cre- and Villin-Cre-positive mice, the 
entire gastrointestinal tract was immediately removed, and the 
stomach was incised along the greater curvature. The intestine was 
dissected into two pieces and designated as colon and small 
intestine, which were cut into equal thirds (duodenum, jejunum, and 
ileum). Each piece of intestine was carefully opened longitudinally 




flushing with ice-cold saline, the intestine was rolled, luminal side 
up from its proximal to distal end, onto a wooden stick and the ends 
of each roll were fixed in place with a 26-gauge needle. After 1 
day of fixation in neutral buffered 10% formalin, the stomach was 
cut into six strips and the rolls of intestine were cut in half with a 
razor blade along the duodenal to the ileal axis.  
 
Quantitative real-time RT-PCR (QRT-PCR)   
For mouse samples, total RNA was isolated from fresh frozen tissue 
using AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. Stroma was trimmed 
out using an H&E-stained top slide, before RNA isolation. 0.3 μg 
of total RNA was reverse transcribed using random hexamers and 
amfiRivertII Reverse Transcriptase (GenDEPOT, Barker, TX) 
according to the manufacturer’s standard protocols.  
For human samples, total RNA was isolated from fresh frozen tissue 
using mirVanaTM Isolation Kit (Ambion), according to the 
manufacturer’s instructions. Stroma was trimmed out using a H&E-
stained top slide, before RNA isolation. Isolated RNA was treated 
with DNase I (Sigma, St. Louis, MO) according to the 
manufacturer’s protocol. Total RNA was reverse transcribed using 
random hexamers by using SuperScript III First-Strand Synthesis 
System (Invitrogen) according to the manufacturer’s standard 
protocol. PCR reactions were performed on a Roche LC480 (Roche 




PCR Master Mix (Qiagen). QRT-PCR primers for mouse gene were 
F: 5'-GCTGCAGGTCTCCTCATG-3' and R: 5'-
CATCCTTCAAATCTCACTCTGC-3' for Cdh1, F: 5'-
GGTCGGTGTGAACGGATTTG-3' and R: 5'-
GTGAGTGGAGTCATACTGGAAC-3' for Gapdh. QRT-PCR 
primers for human gene were F: 5'-
CGCATTGCCACATACACTCTC-3' and R: 5'-
GGTTCCTGGAAGAGCACCTTC-3' for CDH1, and F: 5'-
GAGTCAACGGATTTGGTCG-3' R: 5'-
TGGAATCATATTGGAACATGTAAAC-3' for GAPDH1. 
 
 Genomic DNA quantitative real-time PCR (QPCR)  
Genomic DNA was isolated from 5 fresh frozen tissue samples and 
13 formalin-fixed paraffin-embedded blocks of gastric cancers 
formed in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, using 
AllPrep DNA/RNA/Protein Mini Kit (Qiagen) and QIAamp DNA 
FFPE Tissue Kit (Qiagen) and respectively according to the 
manufacturer’s instructions. PCR reactions were performed in a 
total volume of 10 μl containing 5 μl of QuantiTect Probe PCR kit 
(Qiagen), 400 nM of each primer, 200 nM of TaqMan probe and 60 
ng of genomic DNA using a Roche LC480 (Roche Diagnostics). PCR 
conditions were as follows: 15 min at 95ºC, followed by 99 cycles 
each consisting of 20 s at 94ºC, 20 s at 55ºC, and 20 s at 72ºC. 




TaqMan probe/primers were targeted to exons 6, 8, and 10 of the 






GTCTACCACGTCCACAGTGAC-5', specifically for exon6, exon8 
and exon10 (between LoxP luci) of Cdh1 focusing on only non-
functional Cdh1 allele; Rnu6-F/R, 5'-
GCTTCGGCAGCACATATACTA-3'/5'-







Rnu6 gene was used as a loading control. Tumor data were 
normalized against data obtained for genomic DNA obtained from 
Pdx-1-Cre-negative mice, which was serially diluted as standards 
for quantitation. LOH was defined as the average log2 ratio of three 
probes of tumor to normal DNA < -1.5 (Gutierrez, Dahlberg et al. 




cancers that formed in Pdx-1-Cre; Trp53F/F;Cdh1F/+ mice. 
 
Immunohistochemistry and immunofluorescence 
The mouse tissues and clinical human samples were fixed in 
neutral buffered 10% formalin, processed by standard methods and 
embedded in paraffin. 5 μm cross paraffin sections were dewaxed, 
rehydrated and subjected to antigen retrieval for immunostaining by 
heating at 100°C for 20 minutes in 0.01 M citrate buffer (pH 6.0). 
The ABC method (Vectastain Elite ABC kit and Vectastain M.O.M. 
kit, Vector Laboratories, Burlingame, CA) was used according to 
the manufacturer’s protocol. The slides were subjected to 
colorimetric detection with ImmPact DAB substrate (SK-4105, 
Vector Laboratories). The slides were counterstained with 
Meyer’s hematoxylin for 10 seconds. Negative controls were 
performed by omitting the primary antibody and substitution with 
diluent. The following antibodies were used in this study; rabbit 
polyclonal anti-E-cadherin antibody (1:200; Cell Signaling, #3195, 
Danvers, MA), rabbit polyclonal anti p53 antibody (1:50; Santa Cruz, 
sc-6243), mouse monoclonal anti spasmolytic polypeptide antibody 
(1:50; Abcam, ab49536), mouse monoclonal anti mucin 6 antibody 
(1:100; Novus Biologicals, NB120-11335), mouse monoclonal anti 
mucin 5ac antibody (1:100; Abcam, ab3649), and rabbit polyclonal 




For immunofluorescence analyses, primary antibodies were 
incubated overnight at 4°C and secondary antibodies (FITC goat 
anti-rabbit secondary antibody (1:250; Vector Laboratories FI-
1000)) were incubated for 30 minutes at room temperature. Slides 
were mounted with Vectashield mounting media (Vector 
Laboratories, H-1200). Mouse monoclonal anti Smad4 antibody 
(1:50; Santa Cruz, sc-7966) and rabbit polyclonal anti Ki-67 
antibody (1:200; Abcam, ab15580) were used as primary antibodies. 
At least three 200x microscopic field was examined to assess the 
percentage of Ki-67 positive cells. 
 
Western blot analysis 
Primary cancer cells were collected and lysed with T-PER Tissue 
Protein Extraction Reagent (Thermo Fisher Scientific, Hudson, NH, 
U.S.A) supplemented with protease inhibitor. After removal of 
cellular debris, protein concentration was quantitated by using a 
BCA reagent kit (Thermo Fisher Scientific) according to 
manufacturer’s instruction. Protein sample was prepared by making 
a 3 in 4 dilution with 4x Laemmli sample buffer (250 mM Tris-HCl 
(pH 6.8), 4% SDS, 40% glycerol, 0.05% bromphenol blue, 4% 2-
mercaptoethanol) and boiling for 5 minute. Equal amounts of protein 
were separated on SDS-polyacrylamide gel and transferred onto 
nitrocellulose membrane by electrophoresis and blotting apparatus 




relevant primary antibodies and horseradish peroxidase (HRP)-
conjugated secondary antibodies at the recommended dilutions. 
Rabbit polyclonal anti E-cadherin antibody (1:1000; #3195, Cell 
Signaling, Danvers, MA), rabbit monoclonal anti acetyl H3K9 
(1:1000; #9649, Cell Signaling Technology), and mouse monoclonal 
anti GAPDH (1:1000; sc-32233, Santa Cruz, CA) were applied. 
Immunodetection were performed by using an enhanced 
chemiluminescence (ECL) detection kit (Thermo Fisher Scientific).  
 
Expression array analyses 
Total RNA was isolated from tumor-rich area of fresh frozen 
gastric adenocarcinomas formed in 4 Pdx-1-Cre; Trp53F/F;Cdh1F/+ 
mice and from normal gastric mucosa samples obtained from 4 
Cre-negative mice. 1 μg of total RNA was subjected to GeneChip 
Mouse Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA) and 
summarized with robust multichip average (RMA) using R (version 
2.15.2). Student t-test was used to identify differentially 
expressed genes. Pathway analysis was performed using Gene Set 
Enrichment Analysis (GSEA) (http://www.broadinstitute.org/gsea). 
Genes differentially expressed between tumor and normal samples 
at P<0.001 were subject to the GSEA of canonical pathways and 
transcription factor targets. 
Affymetrix's GeneChip miRNA 2.0 Array was used for microRNA 




test was used to identify microRNAs differentially expressed 
between Pdx-1-Cre;Trp53F/F;Cdh1F/+ gastric adenocarcinomas 
(n=2) and normal tissue (n=2). A P value less than 0.001 was used 
as the cutoff to identify differentially expressed microRNAs. 
 
Bisulfite sequencing 
Genomic DNA was bisulfite-modified and PCR-amplified with 
Cdh1-BGS-F (5'-GTGGAATAGGAAGTTGGGAAGTT-3') and 
Cdh1-MSP-Un-R primers, as in Methylation Specific PCR. After 
PCR products were purified using gel extraction kit (Macrogen, 
Seoul, Korea), the purified PCR products were cloned into the 
TOPO-TA vector (Invitrogen) and transformed of E-coli according 
to the manufacturer’s instructions. After isolation of plasmid DNA 
from 8-10 clones per each sample using plasmid Mini-Prep kit 
(Macrogen), each plasmid sample was sequenced with M13-F (-
20) primer (5'-GTAAAACGACGGCCAG-3'). 
 
Methylation Specific PCR  
For mouse samples, genomic DNA was isolated from gastric 
adenocarcinomas that formed in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice using AllPrep 
DNA/RNA/Protein Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Using macrodissection, stromal tissue 




DNA was bisulfite-converted by using EZ DNA MethylationTM kit 
(Zymo Research, Irvine, CA) according to the manufacturer’s 
protocol. Methylation-specific PCR was performed in a reaction 
volume of 10 μl consisting of 0.05 μl of HotStarTaq (Qiagen), 0.8 
μl of 2.5 mM dNTP, 1 μl of 10× PCR buffer, 2 μl of 5× Q-
Solution, 400 nM of each primer and 1.5 μl of bisulfite-modified 
(20 μl-eluted) genomic DNA sample. The following primers were 
used- F: 5'-TGTTTATTGGTGTGGGAGTTGTG-3' and R: 5'-
CAAAACCCTCCACATACCTACAAC-3' to detect unmethylated 
CpG sites, and F: 5'-GTTTATTGGTGTGGGAGTCGC-3' and R: 
5'-CAAAACCCTCCACATACCTACAAC-3' for methylated CpG 
sites. 
For human samples, genomic DNA samples were isolated from 
fresh frozen gastric tissue of 3 E-cadherin-negative patients, 
using DNeasy Blood & Tissue Kit (Qiagen) according to the 
manufacturer’s protocol. Methylation-specific PCR for human CDH1 
was performed as described above. Primers were designed as 
reported previously (Graff, Herman et al. 1997). The following 
primers were targeted to the CpG island 1; F: 5'-
TAATTTTAGCTTAGAGGGTTATTGT-3' and R: 5'-
CACAACCAATCAACAACACA-3' for unmethylated CpG sites, and 
F: 5'-TTAGGTTAGAGGGTTATCGCGT-3' and R: 5'-
TAACTAAAAATTCACCTACCGAC-3' for methylated CpG sites. 




GGTGGGTGGGTTGTTAGTTTTGT-3' and R: 5'-
AACTCACAAATCTTTACAATTCCAACA-3' for unmethylated CpG 
sites, and F: 5'-GTGGGCGGGTCGTTAGTTTC-3' and R: 5'-
CTCACAAATACTTTACAATTCCGACG-3' for methylated CpG 
sites. The following primers were targeted to the CpG island 3; F: 
5'-GGTAGGTGAATTTTTAGTTAATTAGTGGTA-3' and R: 5'-
ACCCATAACTAACCAAAAACACCA-3' for unmethylated CpG 
sites, and F: 5'-GGTGAATTTTTAGTTAATTAGCGGTAC-3' and 
R: 5'-CATAACTAACCGAAAACGCCG-3' for methylated CpG sites. 
The following primers were targeted to the CpG island 4; F: 5'-
GGGGTGTTTGGTTGTGGAGTTT-3' and R: 5'-
TTCCCTCAAAAATCATCCCCAC-3' for unmethylated CpG sites, 
and F: 5'-GCGTTTGGTCGCGGAGTTC-3' and R: 5'-
TTCCCTCAAAAATCGTCCCCAC-3' for methylated CpG sites. 
 
In vivo 5-aza-2'-deoxycitidine (5-Aza) challenge  
5-aza-2'-deoxycytidine (5-Aza) was purchased from Sigma-
Aldrich (St. Louis, MO). 5-Aza was dissolved in DMSO to a 
concentration of 10 mM. Two Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice were given 2.5 mg/kg of 5-
Aza by intraperitoneal injection in a volume of 1.1 μl DMSO per 
gram body weight (Day 1). The same dose was repeated on Day 3. 




fresh frozen gastric cancer tissue was subjected to RNA isolation 
and real-time RT-PCR as described above. 
 
In vivo Trichostatin A treatment 
Trichostatin A (TSA) was purchased from Sigma-Aldrich. Gastric 
cancer of a Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse was 
harvested at the necropsy, and immediately minced into small tissue 
fragments using scissors and blades in RPMI-1640 media 
supplemented with 10% FBS. Tissue fragments were incubated in 
the media containing TSA for 24 hours. Then, tissue fragments 
were collected and total proteins extraction was performed using 
T-PER Tissue Protein Extraction Reagent (Thermo Fisher 
Scientific).  
 
Exome sequencing of human samples 
Frozen gastric cancer tissue samples and adjacent normal tissue 
samples were obtained, with the IRB approval and signed informed 
consents, from 13 gastric cancer patients who underwent 
gastrectomy at Keimyung University Dongsan Hospital in Taegu, 
Korea, and at Asan Medical Center in Seoul, Korea. Tissue samples 
were cryosectioned and H&E-stained. Guided by the H&E-stained 
top slide, macrodissection was performed for each sample. Median 
tumor nuclei content in all tumor samples was 75%. 20 mg of each 




using metal mortar and pestle. Tissue powder was subjected to 
total RNA and genomic DNA isolation, using mirVana™ Kit (Ambion, 
TX) and DNeasy Blood & Tissue Kit (Qiagen), respectively. Total 
RNA was treated with DNase I (Sigma) using the following reagents: 
1/10 volume of DNase I buffer, 1/10 volume of DNase I, 1/20 
volume of dithiothreotol (DTT, Qiagen) and 1/40 volume of RNass 
inhibitor (RNasin, Promega, WI). Then, the total RNA was purified 
by using Trizol (Ambion), following manufacturer’s instruction. In-
solution RNase A (100mg/ml, Qiagen) treatment was performed for 
isolated genomic DNA. Exome sequencing was performed using 
HiSeq 2000 instrument (Illumina, Hayward, CA), after capturing 
using SureSelect Human All Exon V4+UTR kit (Agilent 
Technologies, Santa Clara, CA). Fastq files were aligned and 
duplicates were removed using BWA and PICARD, respectively. 
Somatic single nucleotide variations were identified and annotated 
using VarScan and Annovar, respectively.  
 
PCR test for Helicobacter pylori (H. pylori) 
Genomic DNA was isolated from fresh frozen tissue sample 
obtained from adjacent normal tissue of 13 young gastric cancer 
patients analyzed in this study. Primers to detect the 16S rDNA 
gene of H. pylori were designed as described in a study of H. pylori 
murine vaccine model (Roussel, Harris et al. 2007). PCR reaction 




dNTP, 1.5 μl of 10× PCR buffer, 500 nM of each primer (F:5'-
TTTGTTAGAGAAGATAATGACGGTATCTAAC-3' and R:5'-
CATAGGATTTCACACCTGACTGACTATC-3'), 3 μl of 5× Q-
solution (Qiagen) and 30 ng of genomic DNA in a final volume of 15 
μl. Cycling conditions were as follows: 2 min at 95°C, followed by 
60 cycles each consisting of 35 s at 94°C, 30 s at 57°C and 30 s at 
72°C, and 3 min at 72°C. Distilled water and H. pylori DNA (1 mM 
and 0.1 mM, mixed with SNU-16 cells), was used as negative and 






Gastric tumors formed in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice recapitulate human diffuse-type gastric adenocarcinomas 
Twenty one of 25 Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice 
(84%) developed spontaneous tumors in the glandular stomach 
(Table 1). The most common cause of death in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice was duodenal obstruction, 
followed by gastric outlet obstruction. Grossly, these mutant mice 
developed ulceroinfiltrative gastric tumors mainly at pyloric antrum 
and gastroduodenal junction (Fig 1Aii). Histologically, tumors 
arising in the glandular stomach of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice resemble human diffuse-type 
gastric adenocarcinomas based on the H&E findings, and were 
invasive into muscle layers and regional lymph nodes (Fig 1B).  
Duodenal adenocarcinomas and forestomach squamous cell 
carcinomas were also identified in 36% and 24% of these mice, 
respectively (Table 1). In addition, 2 mice were noted to have 
adenocarcinomas in the pancreas (8%), which were interpreted as 
invasion of primary duodenal or gastric adenocarcinomas. This 
pattern of tumor distribution is consistent with the known tissue-
specificity of the Pdx-1 promoter (Larsson, Madsen et al. 1996).  
Since gastric adenocarcinoma was the most common type of 




focused our analysis on adenocarcinomas arising in the glandular 
stomach. DNA microarray and immunohistochemistry analyses of  
gastric cancers arising from Pdx-1-Cre;Trp53F/F;Cdh1F/+ mice 
compared to normal stomach epithelium revealed that these tumors 
were positive for mucin 6 and TFF2, and negative for mucin 5a, 
pepsinogen C, somatostatin, and gastric intrinsic factors, suggesting 
the deep antral gland origin of these tumors (Ho, Takamura et al. 

































Fig 1. (A) Representative gross feature of a gastric cancer 
(arrows), an ulceroinfiltrative mass in the antral mucosa, arising 
in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (Aii). Gastric lumen 
of a Pdx-1-Cre-negative mouse of the same age is shown for 
comparison (Ai). (B) Representative histologic findings of the 
gastric cancer (Bi) and lymph node metastasis (Bii). Boxed regions 
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Fig 2. (A) Immunohistochemistry for the tissue origin of the gastric 
adenocarcinomas arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+  
mice. Bar=100 μm.(B) Immunofluorescence and 
immunohistochemistry for the confirmation of loss of Smad4 and 




E-cadherin loss is required for the development of diffuse-type 
gastric adenocarcinoma 
Scheduled sacrifices performed at 4 and 5 months revealed no 
gastric premalignant lesions, such as atrophic gastritis, metaplasia, 
or dysplasia, in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. In 2 of 
4 Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice screened at 6 
months of age, intramucosal adenocarcinomas were observed (Fig 
3Ai). Interestingly, E-cadherin immunostaining was lost in 
adenocarcinoma cells by 6 months of age, suggesting that E-
cadherin loss is an early event required for the diffuse-type gastric 
carcinogenesis in mice.  
To further evaluate the role of E-cadherin in constraining diffuse-
type gastric carcinogenesis, a cohort (n=25) of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice was compared with a cohort 
(n=28) of Pdx-1-Cre;Smad4F/F;Trp53F/F mice. The median gastric 
adenocarcinoma-free survival of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ was 8.0 months, while only one 
gastric adenocarcinoma was identified by a scheduled sacrifice at 9 
month of age, in the Pdx-1-Cre;Smad4F/F;Trp53F/F mouse cohort 
[Log-rank P<0.001] (Fig 3B). Whereas E-cadherin was retained in 
a gastric adenocarcinoma arising in Pdx-1-Cre;Smad4F/F;Trp53F/F 
(Fig 3Aii). 
E-cadherin loss in the stomach epithelium was also identified in a 
gastric adenocarcinoma arising in our Villin-Cre-positive mice (Fig 
































Fig 3. (A) Representative E-cadherin immunohistochemical staining 
of gastric adenocarcinomas arising in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice at 6 and 9 months of age (Ai). 
Gastric adenocaricnoma arising in a Pdx-1-Cre;Smad4F/F;Trp53F/F  
mouse demonstrates strong membranous staining of E-cadherin 
(Aii). (B) Gastric adenocarcinoma-free survivals of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ (n=25) compared with Pdx-1-
Cre;Smad4F/F;Trp53F/F mice (n=28). (C) Loss of E-cadherin 
expression in stomach cancer arising in Villin-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse. The boxed region of left 





E-cadherin was retained in intestinal and mammary 
adenocarcinomas of Cdh1 heterozygotes 
All of the gastric adenocarcinomas arising in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice were negative for E-cadherin 
immunostaining, and all of the gastric adenocarcinomas analyzed 
from this group were also found to express low levels of Cdh1 
mRNA compared with normal tissue (Fig 4A and 4B).  
In contrast to the differences in the incidences of gastric 
adenocarcinomas between the genotypes, duodenal 
adenocarcinoma-free survival was similar between Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ and Pdx-1-Cre;Smad4F/F;Trp53F/F 
mice [9.0 vs 9.1 months; Log-rank P=0.15] (Fig 5A). E-cadherin 
was retained in duodenal adenocarcinomas arising in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, and, therefore, was relatively 
overexpressed compared with gastric adenocarcinomas from the 
same mice (Fig 4A and 4B). Next, we evaluated intestinal and 
mammary adenocarcinomas in mice created through the loss of the 
same set of genes using Villin-Cre and MMTV-Cre transgenes, 
respectively, to compare the tumor promoting effects of E-cadherin 
heterozygosity across the different target tissues. Intestinal 
adenocarcinoma-free survival was similar between Villin-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ and Villin-Cre;Smad4F/F;Trp53F/F 
mice [5.2 vs 5.4 months; Log-rank P=0.27] (Fig 5B). No distant 




Villin-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse developing skin 
metastasis. E-cadherin was retained in intestinal adenocarcinomas 
formed in Villin-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (Fig 4A and 
4B). MMTV-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ and MMTV-
Cre;Smad4F/F;Trp53F/F mice were also not different in the mammary 
carcinoma-free survival [10.4 vs 12.1 months; Log-rank P=0.73] 
and lung metastasis [33.3% (3/9) vs 35.7% (5/14), respectively; P 
for Chi-square test=0.91] (Fig 5C). Histologically, MMTV-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ tumors were invasive ductal 
carcinomas with a squamous component (Fig 6). Mammary 
adenocarcinomas arising in MMTV-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice also retained E-cadherin (Fig 4A and 4B), perhaps accounting 
for why lobular carcinomas were not observed in this model as has 
been reported in K14cre;Trp53F/F;Cdh1F/F (Derksen, Liu et al. 2006). These 
results clearly demonstrate that E-cadherin loss is important for 
the development of gastric adenocarcinomas, but not for the 













Fig 4. (A) E-cadherin immunostaining of gastric adenocarcinomas 
in upper panels( #6, #9, and #16) arising in three representative 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, duodenal 
adenocarcinoma (DU) from Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice, colorectal adenocarcinoma (CO) from Villin-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, and mammary adenocarcinoma 
(MA) from MMTV-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. (B) RNA 
expression levels from Real-time RT-PCR and DNA microarray 
analysis (in linear scales) for Cdh1 of tumors relative to normal 

























Fig 5. (A) Duodenal adenocarcinoma-free survival of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice compared with Pdx-1-
Cre;Smad4F/F;Trp53F/F mice. (B) Colorectal adenocarcinoma-free 
survival of Villin-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice compared 
with Villin-Cre;Smad4F/F;Trp53F/F mice. (C) Mammary 
adenocarcinoma-free survival of MMTV-

























Fig 6. Histopathological findings of mammary adenocarcinoma 
arising in MMTV-Cre;Smad4F/F;Trp53F/F;Cdh1F/+. (A) These 
tumors showed morphological features of invasive ductal 




E-cadherin loss was not related to DNA promoter methylation. 
First of all, we investigated the promoter hypermethylation of 
Cdh1 of these mouse gastric cancers because it is identified in up to 
80% of patients with diffuse-type gastric cancers and is the most 
common second hit in the inactivation of wild type CDH1 allele. 
Methylation-specific PCR and bisulfite genomic sequencing 
analyses of the Cdh1 promoter in these gastric adenocarcinomas did 
not show any evidence for Cdh1 promoter hypermethylation (Fig 
7A). Moreover, the treatment with 5-aza-deoxycitidine (5-Aza), a 
demethylating agent, on these mutant mice bearing gastric cancer 
did not up-regulate E-cadherin (Fig 7B). Next, we investigated 
other epigenetic changes leading to the loss of E-cadherin such as 
histone deacethylation and microRNA regulation. E-cadherin was 
not up-regulated in the tissue explants of a gastric adenocarcinoma 
from a Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse after 24-
h exposure to TSA, inhibitor of histone deacetylase (Fig 8A). 
MicroRNA microarray analyses revealed no differences in 
expression levels of microRNAs targeting Cdh1, such as miR-9, 
between Pdx-1-Cre;Trp53F/F;Cdh1F/+ gastric adenocarcinomas and 
normal tissue (data not shown). LOH was not the major cause of 
E-cadherin loss because LOH at the Cdh1 locus was identified in 2 
of 17 Pdx-1-Cre;Trp53F/F;Cdh1F/+ gastric adenocarcinomas tested 
(11.8%) (Fig 8B). Finally, to investigate the transcriptional 




we additionally performed DNA microarray analysis of duodenal 
cancers arising in these Chd1 heterozygous mice. However, mRNA 
expression levels of these families were high both in the gastric and 
duodenal tumors compared with normal tissue, and were not 
different between the gastric cancer tumors which lost E-cad 
expression and the duodenal cancers which maintained E-cad 

























Fig 7. (Ai) Methylation-specific PCR of the mouse gastric 
carcinomas shown in Fig 4A. (Aii) Bisulfite genomic sequencing 
analyses of the Cdh1 promoter in these gastric adenocarcinomas. 
Open and closed circles represent unmethylated (U) and methylated 
(M) CpG sites, respectively (TSS, transcription start site). A black 
bar indicates a CpG site targeted by (Ai). (B) E-cadherin 
immunostaining (top panels; Inset, E-cadherin-positive adjacent 
normal gastric mucosa) and real-time RT-PCR for gastric 
adenocarcinomas from two Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (#5 and #11) treated with 5-
aza-deoxycitidine (5-Aza). Mice were sacrificed 3 days after 
intraperitoneal injections of 2.5mg/kg of 5-aza on days 1 and 3. 
Gastric mucosa of a Cre-negative mouse (WT) and a gastric 
adenocarcinoma from untreated Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse (Mutant) were used as 
references. E-cadherin was not significantly up-regulated after 5-


















Fig 8. (A) Western blot analysis for E-cadherin of the tissue 
explants of a gastric adenocarcinoma from a Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mouse after 24-h exposure to 0.1 
μM and 0.3 μM of TSA. Acetyl- histone H3 lysine 9 (H3K9ac) 
was immunoblotted as a positive control. (B) Genomic DNA real-
time PCR for the Cdh1 gene in adenocarcinomas arising in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice to evaluate LOH. Log2 ratio of 
each tumor to Cre-negative gastric mucosa is depicted. LOH was 
defined as the average log2 ratio of three probes (for exons 6, 8, 




Comparisons with human diffuse-type gastric cancers 
It was surprising to us that the Cdh1 promoter was not 
significantly methylated in gastric adenocarcinomas formed in our 
Cdh1 heterozygous mice. In human diffuse-type gastric cancers, 
the CDH1 promoter hypermethylation has been identified in up to 
80% of patients. To gain further insight into the clinical relevance of 
this mouse tumor data, we examined the E-cadherin mutation 
profiles of 13 young (≤ 40 years old) Korean gastric cancer 
patients (Table 2). Three of 13 (23.1%) patients demonstrated 
very low levels of E-cadherin immunostaining and mRNA 
expression (Fig 9A and 9B), and one of them harbored a germline 
missense CDH1 mutation (c.1018A>G (p.T340A)) (Fig 10) that 
was previously reported in a hereditary diffuse gastric cancer 
kindred (Oliveira, Bordin et al. 2002). Promoter hypermethylation 
of the CDH1 gene was not identified in any of the three E-
cadherin-negative patients (Fig 11). Thus, transcriptional 
repression of CDH1 possibly due to epigenetic changes other than 
promoter methylation may be a mechanism for E-cadherin 








       E-cadherin immunostaining 
 
 
Positive (n=10) Negative (n=3) 
 
Median age (yr) 35.5 36.5 
 
Female 6 (60%) 1 (33%) 
 
H. pylori-negative 2 (20%) 2 (66.7%) 
 
Histologic type 
   
  Poorly differentiated tubular 5 (50%) 2 (66.7%) 
 
  Signet ring cell carcinoma 5 (50%) 1 (33.3%) 
 
Stage, AJCC 
   
  II 1 (10%) 2 (66.7%) 
 
  III 2 (20%) 1 (33.3%) 
 
  IV 7 (70%) 0 
 
 





























Fig 9. (A) E-cadherin immunostaining of an early-onset human 
gastric cancer. Adjacent normal tissue of the same patient was 
positive (inset). (B) The CDH1 real-time RT-PCR expression 






Fig 10. Direct sequencing analysis of the region of the mutation 
using Buffy coat genomic DNA from the patient with CDH1 























Fig 11. (A) Methylation-specific PCR analysis of human gastric 
cancers for CpG sites of CDH1 promoter, demonstrating no evidence 
of significant CDH1 promoter hypermethylation (U, unmethylated; M, 
methylated CpG sites). (B) Bisulfite genomic sequencing analysis of 
the Cdh1 promoter in the gastric cancer with a germline missense 






Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice described in this study 
are unique in several aspects. In contrast to previously reported 
spontaneous murine gastric tumors, which are of parietal cell or 
neuroendocrine lineage (Graff, Herman et al. 1997; Roussel, Harris 
et al. 2007; Gutierrez, Dahlberg et al. 2010; Shimada, Mimata et al. 
2012), gastric adenocarcinomas formed in these mice are of the 
mucus-secreting gastric epithelial cell origin. In addition, tumor 
suppressor genes most commonly inactivated in human diffuse-
type gastric adenocarcinomas were targeted to be knocked-out in 
the gastroduodenal epithelium of this model (Becker, Atkinson et al. 
1994; Maesawa, Tamura et al. 1995; Schmierer and Hill 2007; 
Wang, Kim et al. 2007). While Smad4 is inactivated in 40% of 
human gastric cancers (Wang, Kim et al. 2007), functional roles of 
Smad4 in gastric cancer progression have not been fully evaluated 
using in vivo models. This study provides functional evidence for 
the role of Smad4 in suppressing gastric cancer progression. 
Although this study focused on gastric adenocarcinomas, it also 
demonstrates a role of Smad4 in suppressing duodenal carcinomas. 
While Pdx-1-Cre;Trp53F/F;Cdh1F/F mice developed no duodenal 
carcinomas, the additional loss of Smad4 significantly promoted 
duodenal carcinomas (Table 1), confirming that Smad4 loss in the 




1998). Possibly, if Pdx-1-Cre; Smad4F/F;Trp53F/F mice did not die 
of duodenal obstruction, they might have developed gastric or even 
pancreatic cancers at later time points. 
The specific role of E-cadherin loss in the development of 
diffuse-type gastric adenocarcinomas was clearly documented by 
this cross-tissue tumorigenesis study. These results validate and 
extend a prior study suggesting a role for E-cadherin in the 
development of gastric cancer (Shimada, Mimata et al. 2012). The 
inactivation of the wild type CDH1 allele in germline mutation 
carriers is generally thought to be promoted by environmental and 
physiological factors such as diet, carcinogen exposure and 
inflammation (Sirard, de la Pompa et al. 1998; Machado, Oliveira et 
al. 2001; Rosivatz, Becker et al. 2002). Humar, et al. reported that 
E-cadherin loss is a consistent finding in the MNU-induced gastric 
cancer model (Humar, Blair et al. 2009). In contrast, E-cadherin 
expression was lost in gastric tumors from our mutant mice 
carrying one mutant allele without any exposure to exogenous 
carcinogens (Oliveira, Sousa et al. 2009). E-cadherin loss in the 
stomach epithelium was also identified in a gastric adenocarcinoma 
arising in our Villin-Cre-positive mice (Fig 4), and is therefore not 
limited to the Pdx-1 developmental context. In contrast to breast 
cancers arising in humans with germline E-cadherin mutation, 
mammary adenocarcinomas arising in MMTV-




expression, and were not more aggressive than tumors arising in 
MMTV-Cre;Smad4F/F;Trp53F/F mice. Thus, the selection pressure 
for E-cadherin loss may be relatively low in the context of the 
mouse mammary gland, compared with the stomach. This is 
consistent with the lower lifetime risk for breast cancer than for 
stomach cancer in germline E-cadherin mutation carriers (Pharoah, 
Guilford et al. 2001). Studies are ongoing in our laboratory to 
identify gastric tissue-specific epigenetic events or signaling 
pathway activation leading to E-cadherin loss that may be 










LOSS OF E-CADHERIN AND SMAD4 COOPERATE TO PROMOTE 







 To date, only a few genetically-engineered mouse models of 
gastric cancer have been reported, and none of them develop 
distant metastasis. Notably, 14.3% of gastric adenocarcinomas 
arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice metastasized 
to the lung, which is a highly unique finding for a genetically 
engineered mouse model for gastric cancers. To dissect the roles of 
E-cadherin and Smad4 in gastric cancer progression and 
metastasis, we generated Smad4 intact mutant mice, Pdx-1-Cre; 
Trp53F/F;Cdh1F/F mice. Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice 
developed gastric adenocarcinomas more rapidly than Pdx-1-
Cre;F/F;Trp53 F/F;Cdh1F/F mice and the gastric adenocarcinomas 
formed in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice were more 
invasive than those arising in Pdx-1-Cre; Trp53F/F;Cdh1F/F mice. 
Lung metastases were not identified in Pdx-1-
Cre;Trp53F/F;Cdh1Ff+ mice. Nuclear β-catenin accumulation was 
identified at the invasive tumor front of gastric adenocarcinomas 
arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice while this 
phenotype was less prominent in mice with intact E-cadherin or 
Smad4, indicating that the inhibition of β-catenin signaling by E-
cadherin or Smad4 may down-regulate signaling pathways involved 
in metastases in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. 
Knockdown of β-catenin significantly inhibited migratory activity 
of Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cell lines. Thus, loss of 
E-cadherin and Smad4 cooperate with p53 loss to promote the 





E-cadherin, an epithelial cell adhesion molecule is on protein 
prominently associated with tumor invasiveness and metastasis on 
progression of cancers (Fukamachi, Shimada et al. 2011; Qiao and 
Gumucio 2011; Jaiswal, Breitsprecher et al. 2013). E-cadherin loss 
in cancer contributes to metastasis by inducing wide-range of 
transcriptional and functional change as well as disruption of cell to 
cell contacts (Pharoah, Guilford et al. 2001). E-cadherin loss 
influenced localization pattern and activation of the E-cadherin 
binding partnerβ-catenin (Pharoah, Guilford et al. 2001), which 
has been associated with the induction of EMTs in various contexts. 
Recent study showed that Atp4b-Cre;Cdh1F/F;Trp53F/F mice 
developed diffuse-type gastric cancers . However this mouse 
gastric cancers did not metastasize to the distant visceral organs 
and nuclear β-catenin accumulation was not detected in the 
tumors (Shimada, Mimata et al. 2012). Thus, gastric cancer 
metastasis may require a concerted action of key molecular events 
in addition to loss of E-cadherin. 
Smad4 is a co-Smad involved in both branches of the TGF-
β/BMP signaling system (Schmierer and Hill 2007). The anti-
metastatic role of Smad4 in gastric cancer, which has not been 
previously demonstrated in vivo, is in line with previous data for 
colorectal and prostate cancers (Takaku, Oshima et al. 1998; Humar, 




of Smad4 may include suppression of proliferation, leading to 
proliferative dormancy (Oliveira, Sousa et al. 2009).  
To date, only a few genetically-engineered mouse models of 
gastric cancer have been reported, and none of them develop 
distant metastases. Notably, 14.3% of gastric adenocarcinomas 
arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice metastasized 
to the lung, which is a highly unique finding for a genetically 
engineered mouse model for gastric cancers. We demonstrated that 
the metastatic phenotype of Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice may be attributable in part to Smad4 loss-induced β-catenin 
activation following E-cadherin loss. The metastatic phenotype of 
our mutant mice provides a unique opportunity to dissect the roles 
of E-cadherin and Smad4 in gastric cancer progression, and in 






Materials and Methods 
 
Mice 
Mouse studies were conducted with the approval of the Animal 
Care and Use Committees of National Cancer Center of Korea and 
the National Cancer Institute, Bethesda, MD. Pdx-1-Cre mice 
(B6.FVB-Tg(Ipf1-cre)1Tuv), originally generated by Dr. Lowy 
(Hingorani, Petricoin et al. 2003), were provided through the Mouse 
Models of Human Cancers Consortium (MMHCC) repository at the 
NCI Frederick Cancer Research Center. FVB.129-Trp53tm1Brn 
(Jonkers, Meuwissen et al. 2001) mice were also provided by the 
MMHCC. B6.129-Cdh1tm2Kem/J mice, which have loxP sites flanking 
exons 6-10, were purchased from The Jackson Laboratory 
(Boussadia, Kutsch et al. 2002). Conditional Smad4 knockout mice 
(Smad4F/F) on the Black Swiss, B6 and 129 backgrounds were 
previously described (Yang, Li et al. 2002).  
Compound conditional knockouts of Smad4, p53, and E-cadherin 
were bred with Pdx-1-Cre mice. Offspring mice were genotyped 
using polymerase chain reaction (PCR) assays for tail DNA. PCR 
genotyping primers were previously listed in Chapter I. 
 
Quantitative real-time RT-PCR (QRT-PCR)   
For mouse samples, total RNA was isolated from fresh frozen 
tissue using AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, 




trimmed out using an H&E-stained top slide, before RNA isolation. 
0.3 μg of total RNA was reverse transcribed using random 
hexamers and amfiRivertII Reverse Transcriptase (GenDEPOT, 
Barker, TX) according to the manufacturer’s standard protocols.  
For human samples, total RNA was isolated from fresh frozen tissue 
using mirVanaTM Isolation Kit (Ambion), according to the 
manufacturer’s instructions. Stroma was trimmed out using a H&E-
stained top slide, before RNA isolation. Isolated RNA was treated 
with DNase I (Sigma, St. Louis, MO) according to the 
manufacturer’s protocol. Total RNA was reverse transcribed using 
random hexamers by using SuperScript III First-Strand Synthesis 
System (Invitrogen) according to the manufacturer’s standard 
protocol. PCR reactions were performed on a Roche LC480 (Roche 
Diagnostics, Penzberg, Germany) using QuantiTect SYBR Green 
PCR Master Mix (Qiagen). QRT-PCR primers for mouse gene were 
F: 5'-ACGATGAGGACCAGGTGGTAG-3' and  
R: 5'-CAGTACAACGAGCTGTCTCTAC-3' for Ctnnb1,  
F: 5'-GTGCGCCAGCAGTATGAAAG-3' and  
R: 5'-GCATCGTTGTTCCGGTTGG-3' for Vim,  
F: 5'-ACTTACCTCGGATCGTAGTG-3' and  
R: 5'-TCTCCATGATCTCTCCTTGC-3' for Mmp7,  
F: 5'-ATCCTGGTGCCTTGATGTAC-3' and  
R: 5'-GTCTGAAGGTCCATAGATTGTC-3' for Mmp8,  




R: 5'-TTACAGCTACCTGCCACTTTTC-3' for Cdh2,  
F: 5'-CACACGCTGCCTTGTGTCT-3' and  
R: 5'-GGTCAGCAAAAGCACGGTT-3' for Snai1,  
F: 5'-CCTTGGGGCGTGTAAGTCC-3' and  
R: 5'-TTCTCAGCTTCGATGGCATGG-3' for Snai2,  
F: 5'-TGATGAAAACGGAACACCAGATG-3' and  
R: 5'-GTTGTCCTCGTTCTTCTCATGG-3' for Zeb1,  
F: 5'-AGCGACACGGCCATTATTTAC-3' and  
R: 5'-GTTGGGCAAAAGCATCTGGAG-3' for Zeb2,  
F: 5'-GGACAAGCTGAGCAAGATTCA-3' and  
R: 5'-CGGAGAAGGCGTAGCTGAG-3' for Twist1,   
F: 5'-ACGAGCGTCTCAGCTACGCC-3' and  
R: 5'-AGGTGGGTCCTGGCTTGCGG-3' for Twist2 and  
F: 5'-GGTCGGTGTGAACGGATTTG-3' and  
R: 5'-GTGAGTGGAGTCATACTGGAAC-3' for Gapdh.  
 
Primary cell culture from mouse cancer tissue  
Tumor arising in these mutant mice was minced into small pieces 
and digested with collagenase for 30 min at 37˚C. Single tumor 
cells were seeded into plated on a 60-mm dish in RPMI 1640 media 
with 20% fetal bovine serum (FBS), 100 U/ml of penicillin, and 0.1 
mg/ml of streptomycin in humidified incubator at 37˚C in an 





Immunohistochemistry and immunofluorescence 
The mouse tissues were fixed in neutral buffered 10% formalin, 
processed by standard methods and embedded in paraffin. 5 μm 
cross paraffin sections were dewaxed, rehydrated and subjected to 
antigen retrieval for immunostaining by heating at 100°C for 20 
minutes in 0.01 M citrate buffer (pH 6.0). The ABC method 
(Vectastain Elite ABC kit and Vectastain M.O.M. kit, Vector 
Laboratories, Burlingame, CA) was used according to the 
manufacturer’s protocol. The slides were subjected to colorimetric 
detection with ImmPact DAB substrate (SK-4105, Vector 
Laboratories). The slides were counterstained with Meyer’s 
hematoxylin for 10 seconds. Negative controls were performed by 
omitting the primary antibody and substitution with diluent. The 
following antibodies were used in this study; rabbit polyclonal anti 
E-cadherin antibody (1:200; Cell Signaling, #3195), mouse 
monoclonal anti β-catenin antibody (1:200; BD, 610154), rabbit 
monoclonal anti Vimentin antibody (1:100; Cell signaling, #5741), 
rabbit monoclonal anti MMP7 antibody (1:100; Cell signaling, 
#3801), and rabbit monoclonal anti MMP8 antibody (1:100; Abcam, 
ab81286). 
 Positive cells for β-catenin was defined as tumor cells showing a 
distinct nuclear staining. Unequivocal immunohistochemical staining 
in tumor nucleus, as compared with normal gastric mucosa, was 




vimentin staining was defined as a strong cytoplasmic signal 
equivalent to that of normal mesenchymal tissues. A positive MMP7 
staining was defined as a strong cytoplasmic signal which was 
unequivocally deeper than the background. At least three 200x 
microscopic fields at the invasive front were examined by a 
pathologist to determine the average percentage of cells with 
positive β-catenin, vimentin, and MMP-7 staining. Differences in 
the percentage of positive immunostaining between genotypes were 
evaluated using Student t-test. 
For immunofluorescence analyses, primary antibodies were 
incubated overnight at 4°C and secondary antibodies (FITC goat 
anti-rabbit secondary antibody (1:250; Vector Laboratories FI-
1000)) were incubated for 30 minutes at room temperature. Slides 
were mounted with Vectashield mounting media (Vector 
Laboratories, H-1200). Rabbit polyclonal anti Ki-67 antibody 
(1:200; Abcam, ab15580) were used as primary antibodies. At least 
three 200x microscopic field was examined to assess the 
percentage of Ki-67 positive cells.  
To stain the β-catenin in primary cultured cells, cells were 
seeded on coated coverslips with poly-L-lysine (P4707, Sigma, St. 
Louis, MO) at 1 x 105 cells per coverslip. After cells were grown 
for 24 hours at 37°C, the cells were fixed in ice-cold methanol for 
10 minutes and blocked with PBS containing 5% of normal goat 




catenin antibody (1:100) overnight at 4°C, washed with PBS, and 
then incubated with Alexa Fluor 594 goat anti-mouse antibody 
(1:100; Life Technologies, A-11005, Carlsbad, CA) for 2 hours. 
Cells were imaged using using Axiovert 200M (Carl Zeiss, 
Oberkochen, Germany). 
 
Western blot analysis 
Mouse cancer cells were collected and lysed with T-PER Tissue 
Protein Extraction Reagent (Thermo Fisher Scientific, Hudson, NH, 
U.S.A) supplemented with protease inhibitors. After removal of 
cellular debris, protein concentration was quantitated by using a 
BCA reagent kit (Thermo Fisher Scientific) according to 
manufacturer’s instruction. Equal amounts of protein were 
separated on SDS-polyacrylamide gel and transferred onto 
nitrocellulose membrane by electrophoresis and blotting apparatus 
(Bio-Rad, Hercules, CA). The proteins were probed with the 
relevant primary antibodies and horseradish peroxidase (HRP)-
conjugated secondary antibodies at the recommended dilutions. 
Rabbit polyclonal anti E-cadherin antibody (1:1000; #3195, Cell 
Signaling, Danvers, MA), mouse monoclonal anti β-catenin 
antibody (1:1000; 610154, BD Transduction Laboratories), rabbit 
monoclonal anti Vimentin antibody (1:100; Cell signaling, #5741), 
and mouse monoclonal anti GAPDH (1:1000; sc-32233, Santa Cruz, 




enhanced chemiluminescence (ECL) detection kit (Thermo Fisher 
Scientific).  
 
Measurement of β-catenin activity 
β-catenin activities in primary cultured cancer cell lines were 
evaluated by using Cignal TCF/LEF reporter assay kit (CCS-018L, 
SA Biosciences, Frederick, MD). Primary cultured cells (2.5 x 104 
cell per well) were plated in 24 wells 12 h before transfection. 
These cells were transiently transfected with the TCF/LEF 
reporter plasmid according to the protocol of the manufacturer 
using Lipofectamine 2000 transfection reagent (Life Technologies). 
24 hours after the transfection, Opti-MEM medium was changed to 
RPMI 1640 containing 10% FBS. The cells were allowed to grow for 
one more day and luciferase assays were carried out using the dual 
luciferase reporter assay system (Promega, Madison, WI) 
according to the manufacturer’s protocol. Light emission was 
quantified with a Victor 3 1420 luminescence microplate reader 
(Perkin-Elmer, Waltham, MA). The signals were normalized for 
transfection efficiency to the internal Renilla control. 
 
Establishment of stable β-catenin knock down cells  
The lentiviral Ctnnb1 shRNA constructs were purchased from 
Sigma-Aldrich (St. Louis, MO) with pLKO.1-puro eGFP control 








AGGCTTGGGTTTTT. Lentiviruses were produced by 
cotransfecting shRNA-expressing vector and pMD2.G and psPAX2 
constructs (Addgene) into 293T cells by using lipofectamine 2000 
(Invitrogen). Viral supernatants were harvested 48 hours after 
transfection, filtered though a 0.45 μm filter, titered, and used to 
infect primary cultured cancer cells with 10 μg/mL polybrene. 
Cells were treated by 2 μg/mL puromycin at 48 hours after viral 
transduction and were selected for 3 days. 
To measure monolayer growth rates of these cells, the cells were 
seeded on tissue culture 24 well plates at 2.5 x 104 cells/well in 
RPMI 1640 media containing 10% FBS. At 24 hours after seeding, 
the growth rates were evaluated by manual cell counting. 
 
Migration assay 
Primary cultured cells were plated on 24-well inserts with 8 μm 
pore (353097, BD) at 2.5 x 104/well in serum-free RPMI 1640 
media. Media containing 10% FBS was added to 24-well insert 
plate (354578, BD) and cells were cultured at 37°C and 5% CO2. At 
24 h after plating, remaining cells were removed by gently 




were fixed with 10% formalin for 10 min and washed with PBS once. 
The inserts were soaked in hematoxylin for 1 min and eosin for 5 
min and then washed with tap water several times. Membranes 
were cut from inserts and moved to a glass slide. A few drops of 
Permount (Fisher Scientific, Waltham, MA) were added onto the 
membrane and the glass side was covered with cover slide evenly. 
The number of migrated cells was averaged by counting 3 high 







Smad4 cooperates with E-cadherin in constraining the development 
of gastric adenocarcinoma by inhibiting cell cycle progression 
No neoplastic lesions were found at the time of necropsy of Pdx-
1-Cre;Trp53F/F;Cdh1F/+ mice (Fig 1A). These results suggest that 
loss of Smad4 was required for the development of gastric 
adenocarcinoma in Pdx-1-Cre;Trp53F/F;Cdh1F/+ mice [Log-rank 
P=0.005]. Since all of the Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice analyzed were found to develop E-cadherin-negative gastric 
adenocarcinomas, tumors from those mice were compared with 
tumors from Pdx-1-Cre;Trp53F/F;Cdh1F/F mice. Six mice in the 
Pdx-1-Cre;Trp53F/F;Cdh1F/F cohort (n=15) developed gastric 
adenocarcinomas with a median tumor-free survival of 9.4 months 
for this group (Fig 1A), but did not develop distant metastases. 
This phenotype is consistent with that of the previously reported 
Atb4-Cre;Trp53F/F;Cdh1F/F mice (Shimada, Mimata et al. 2012). 
Gastric adenocarcinoma-free survival was significantly longer in 
Pdx-1-Cre;Trp53F/F;Cdh1F/F mice than in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice [median, 9.4 vs 8.0 months; 
Log-rank P=0.007], demonstrating the role of Smad4 in 
constraining gastric cancer progression (Fig 1A). Gastric 
adenocarcinomas formed in Pdx-1-Cre;Trp53F/F;Cdh1F/F mice were 




Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (Fig 1B). Gastric 
adenocarcinomas formed in Pdx-1-Cre;Trp53F/F;Cdh1F/F mice 
exhibited lower Ki-67 positivity than Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice [median, 42.8% vs 71.7%, 
respectively; P<0.001], suggesting that Smad4 constrains tumor 







Fig 1. (A) Gastric adenocarcinoma-free survival of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (n=25) compared with Pdx-
1-Cre;Trp53F/F;Cdh1F/F mice (n=15) and with Pdx-1-
Cre;Trp53F/F;Cdh1F/+ mice which developed no tumors (n=7) (B) 
Depth of invasion between gastric adenocaricnomas arising in Pdx-
1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice and Pdx-1-
Cre;Trp53F/F;Cdh1F/F mice at 7 to 9 months of age. -, T1;Mucosa 
and Submucosa, T2; Muscularis propria, T3; Subserosa, T4;Serosa 









Fig 2. (A) E-cadherin and Ki-67 immunoreactivity across 
genotypes. Representative E-cadherin immunohistochemical 
and Ki-67 immunofluoresence staining of gastric adenocarcinomas 
arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ and Pdx-1-
Cre;Trp53F/F;Cdh1F/F. Dotted red lines indicate tumor margins. (B) 
The percentage of Ki-67-positive cells in gastric adenocarcinomas 
arising in Pdx-1-Cre;Trp53F/F;Cdh1F/F mice was lower than that of 




Loss of E-cadherin and Smad4 cooperate to promote lung metastasis 
through the accumulation of nuclear β-catenin 
Importantly, three of 21 Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice with gastric adenocarcinomas (14.2%) developed lung 
metastases (Fig 4). The metastatic lesions had similar 
histopathological features to the primary gastric tumors, including 
the lack of E-cadherin immunostaining (Fig 3). Prompted by the 
GSEA analyses showing the enrichment of Lef1 target genes in the 
gastric cancers arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
mice (Table 1), we sought to evaluate β-catenin immunostaining 
in the mutant mouse tumors. Nuclear β-catenin accumulation was 
identified at the invasive front of gastric adenocarcinomas from 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, suggesting the 
association of nuclear β-catenin accumulation with tumor 
progression [P for t-test between the invasive front and tumor 
center<0.001] (Fig 5). β-catenin target genes, such as MMP7 and 
Vimentin, were focally overexpressed among nuclear β-catenin -
positive carcinoma cells at the invasive front, suggesting an EMT 
(Fig 5). Ki-67 immunostaining was decreased at the invasive front 






Fig 3. H&E (Aii , Aiii) and E-cadherin immunostaining (Aiv) of lung 
metastases of gastric carcinomas arising in three Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (#3, #14, and #22). 




















Fig 4. (A) Metastasis-free survival of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ compared with Pdx-1-Cre; 
Smad4F/F;Trp53F/F mice. (B) Metastasis-free survival of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ compared with Pdx-1-





Table 1. Gene sets most enriched in 1,096 genes upregulated in 
gastric adenocarcinomas at P < 0.001 






Factor Value in gene set Genes 
CAGGTG_V$E12_Q6 Tcf3 <10-16 2485 162 
CAGCTG_V$AP4_Q5 Repin1 <10-16 1524 106 
GATTGGY_V$NFY_Q6_01   <10-16 1160 81 
TTGTTT_V$FOXO4_01 Mllt7 <10-16 2061 151 
CTTTGA_V$LEF1_Q2 Lef1 <10-16 1232 92 
TATAAA_V$TATA_01 Taf <10-16 1296 100 
GGGCGGR_V$SP1_Q6 Sp1 <10-16 2940 229 
GGGAGGRR_V$MAZ_Q6 Maz <10-16 2274 178 
TGACAGNY_V$MEIS1_01 Meis1 <10-16 827 65 
GGGTGGRR_V$PAX4_03 Pax4 <10-16 1294 102 
AACTTT_UNKNOWN   <10-16 1890 151 
CTGCAGY_UNKNOWN   <10-16 765 65 
RNGTGGGC_UNKNOWN   <10-16 766 66 
TGGAAA_V$NFAT_Q4_01 Nfat <10-16 1896 164 
TGANTCA_V$AP1_C Jun <10-16 1121 99 
CTTTGT_V$LEF1_Q2 Lef1 <10-16 1972 182 
RYTTCCTG_V$ETS2_B Ets2 <10-16 1085 111 
TTTNNANAGCYR_UNKNO
WN 
  <10-16 133 29 
KRCTCNNNNMANAGC_UN
KNOWN 









Fig 5. Immunohistochemistry for the tumor center and invasive 
front of gastric cancers formed in Pdx-1-




The loss of E-cadherin and Smad4 expression cooperate to promote 
lung metastasis partly through the β-catenin activation 
A gastric carcinoma from a Pdx-1-Cre;Smad4F/F;Trp53F/F mouse 
did not demonstrate nuclear β-catenin staining (Fig 6A). Duodenal 
carcinomas from Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (n=4), 
with intact E-cadherin expression, also demonstrated significantly 
lower nuclear β-catenin positivity at the invasive front than 
gastric carcinomas from mice with the same genotype (n=14) 
[median, 8.5% vs 29.3%; P for t-test<0.001] (Fig 6B). Invasive 
fronts of these tumors with E-cadherin expression did not express 
vimentin (data not shown). Thus, complete loss of E-cadherin may 
be a prerequisite for nuclear β-catenin accumulation across the 
different epithelial tumor types. The Pdx-1-Cre;Smad4F/F;Trp53F/F 
mouse with a gastric adenocarcinoma had no distant metastases 
[Log-rank P value for metastasis-free survival between Pdx-1-
Cre;Smad4F/F;Trp53F/F and Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+=0.013] (Fig 4A). Given the low 
nuclear β-catenin positivity of the duodenal adenocarcinomas from 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice which do not 
metastasize (Fig 6B), these results suggest the metastatic 
propensity of Pdx-1-Cre;Trp53F/F;Cdh1F/+ mice may be 
attributable, at least in part, to the activation of the β-catenin 
signaling pathway following E-cadherin loss. 




Smad4 (Pdx-1-Cre;Trp53F/F;Cdh1F/+ and Pdx-1-
Cre;Trp53F/F;Cdh1F/F) [Log-rank P=0.035], we investigated 
possible mechanisms for the role of Smad4 in suppressing 
metastasis. Gastric adenocarcinomas arising in Pdx-1-
Cre;Trp53F/F;Cdh1F/F (n=4) demonstrated nuclear β-catenin 
accumulation at the invasive front, but not as frequently as gastric 
adenocarcinomas from Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice 
(n=14), consistent with a prior report (Shimada, Mimata et al. 2012) 
[P for t-test= 0.047] (Fig 6B). Gastric cancers formed in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice demonstrated lower expression 
of Vimentin and MMP7 at the invasive front than those arising from 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice [t-test P values for 
the positivity, 0.021 and 0.037 for vimentin and MMP7, respectively] 
(Fig 7A and 7B). MMP8 expression also tended to be higher in 











Fig 6. (A) Representative immunohistochemistry findings for E-
cadherin and β-catenin at the invasive front of tumors across 
genotypes. (B) Percentage of gastric adenocarcinoma cells at the 
invasive front with nuclear β-catenin immunostaining in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cohort (n=14) and Pdx-1-
Cre;Trp53F/F;Cdh1F/F cohort (n=4) [P for t-test=0.047]. Nuclear 
β-catenin positivity was lower in duodenal carcinomas from Pdx-
1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice that retained E-cadherin 
than gastric adenocarcinomas with the same genotype [P for t-









Fig 7. (A) Vimentin and MMP7 immunohistochemistry at the tumor 
invasive front between Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+  and 
Pdx-1-Cre;Trp53F/F;Cdh1F/F mice. (B) Percentage of Vimentin- 
and MMP7-positive cells were higher in gastric cancer tissues 
arising in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice (n=10)  than 
those in Pdx-1-Cre;Trp53F/F;Cdh1F/F mice (n=5). 
MMP8 expression at the invasive front of gastric cancer of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+  mice as compared with that of Pdx-




Knockdown of β-catenin significantly inhibited migratory activity of 
primary cultured gastric cancer cell lines 
To further evaluate the effect of Smad4 loss on β-catenin 
activity, we established primary cultured cells from gastric 
adenocarcinomas arising from Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ and Pdx-1-Cre;Trp53F/F;Cdh1F/F 
mice. Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ gastric cancer cell 
lines showed higher expression of mesenchymal markers than that 
of Pdx-1-Cre;Trp53F/F;Cdh1F/F gastric cancer cell lines (Fig 8A 
and 8B). Consistent with our in vivo results, Ctnnb1 mRNA 
expression [P<0.001], β-catenin reporter activity [P<0.001], and 
nuclear β-catenin immunoflourescence were higher in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cells than Pdx-1-
Cre;Trp53F/F;Cdh1F/F cells (Fig 9A and 9B). Results using the 
Boyden chamber migration assay revealed that Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cells demonstrated higher migratory 
activity than Pdx-1-Cre;Trp53F/F;Cdh1F/F cells [P<0.001] (Fig 
10A).  
Based upon these results, we performed β-catenin knockdown 
experiments on 2 independent Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cell lines. Knockdown of β-catenin 
in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cells led to mesenchymal-
to-epithelial switch in morphology and gene expression , without 




Importantly, knockdown of β-catenin, using two different short 
hairpin RNAs, significantly inhibited migratory activity of both 
of Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cells [P<0.001] (Fig 11). 
These results collectively suggest that the loss of E-cadherin and 
Smad4 expression cooperate to promote lung metastasis partly 










Fig 8. (A) Mesenchymal marker, Vimentin expression of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+  gastric cancer cell lines by western 
blotting. (B) The expression of mesenchymal markers, Vimentin 
(Vim), and N-cadherin (Cdh2), and epithelial to mesenchymal 
transition regulators, Snail (Snai1), Slug (Snai2), Zeb1, Zeb2, 
Twist1, and Twist2, and matrix metalloproteinases (Mmp7 and 
Mmp8) of Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+  gastric cancer 
cell lines as compared with that of Pdx-1-Cre;Trp53F/F;Cdh1F/F 









Fig 9. (A) Representative mRNA expression (real-time RT-PCR), 
β-catenin reporter activity, and migratory activity of primary 
cultured cells from gastric adenocarcinomas arising from Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ (n=4) and Pdx-1-
Cre;Trp53F/F;Cdh1F/F mice (n=2) from multiple experiments. (B) 
Nuclear β-catenin immunoflourescence of primary cultured cells 
from gastric adenocarcinomas arising from Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ and Pdx-1-Cre;Trp53F/F;Cdh1F/F 











Fig 10. (A) Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cells, that 
originally exhibited a fibroblast, spindle-like shape, acquired 
epithelial, cuboidal cell morphology, after knockdown of β-catenin. 
(B) mRNA expression of MMP7 and MMP8 as well as that of 










Fig 11. (A) Migratory activity of two independent primary cultured 
cells from gastric adenocarcinomas arising from Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice, after knockdown of β-catenin 
using two different short hairpin RNAs. (B) Western blot analysis to 





Gastric adenocarcinomas arising in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice metastasized to the lung, which 
is a highly unique finding for a genetically engineered mouse model 
for gastric cancers. To date, only a few genetically-engineered 
mouse models of gastric cancer have been reported, and none of 
them develop distant metastases (Graff, Herman et al. 1997; 
Derksen, Liu et al. 2006; Roussel, Harris et al. 2007; Gutierrez, 
Dahlberg et al. 2010; Shimada, Mimata et al. 2012). After 
Helicobacter inoculation, insulin-gastrin (INS-GAS) transgenic 
mice develop invasive gastric carcinomas with a frequency of 75% 
(Roussel, Harris et al. 2007), but without distant metastases. Thirty 
percent of mice deficient in pS2 trefoil factor develop multifocal 
intraepithelial or intramucosal carcinomas, but no distant 
metastases (Gutierrez, Dahlberg et al. 2010). Gp130F/F mice lacking 
in the SHP2-binding site on the IL-6 family receptor gp130 
develop gastric cancer with submucosal invasion only (Graff, 
Herman et al. 1997). The K19-C2mE mice expressing COX-2 and 
microsomal prostaglandin E synthase-1 in the stomach develop 
dysplastic tumors in the gastric epithelium (Derksen, Liu et al. 
2006). Atp4b-Cre;Cdh1F/F;Trp53F/F mice develop diffuse-type 
gastric cancers which frequently metastasize to lymph nodes but 
not to the distant visceral organs (Shimada, Mimata et al. 2012). 




key molecular events, including losses of E-cadherin and Smad4, 
as demonstrated in this study. 
The metastatic phenotype of our mutant mice provides a unique 
opportunity to dissect the roles of E-cadherin and Smad4 in gastric 
cancer progression, and in relation to EMT. Without exposure to 
carcinogens, the gastric epithelium of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice lost E-cadherin expression 
and developed adenocarcinomas that progressed through EMT, 
suggesting the importance of EMT in gastric cancer progression. 
Nuclear β-catenin accumulation, suggesting activation of the 
canonical Wnt/ β-catenin pathway, was accompanied by EMT 
phenotype such as vimentin overexpression (Oliveira, Bordin et al. 
2002). Given that this phenotype was not observed in 
gastrointestinal tumors of our mutant mice that retained E-cadherin, 
the unique metastatic phenotype of Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice may be attributable in part to 
the activation of the β-catenin signaling pathway following E-
cadherin loss (Shimada, Mimata et al. 2012). Our 
study also provides functional evidences for the causal role of β-
catenin for the migration process related to metastasis of gastric 
cancer, consistent with data in the literature suggesting that β-
catenin promotes the metastatic progression of breast and 
colorectal cancers by transcriptional activation of vimentin, MMP7, 




al. 1996; Wang, Dangler et al. 2000; Judd, Alderman et al. 2004; 
Shimada, Mimata et al. 2012). 
The anti-metastatic role of Smad4 in gastric cancer, which has 
not been previously demonstrated in vivo, is in line with previous 
data for colorectal and prostate cancers (Takaku, Oshima et al. 
1998; Humar, Blair et al. 2009). Notably, nuclear β-catenin 
accumulation at the invasive front was more prominent in our Pdx-
1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice than in Pdx-1-
Cre;Trp53F/F;Cdh1F/F, which is partly consistent with a report by 
Shimada, et al. that E-cadherin-/-; p53-/- mice do not 
overexpress β-catenin (Shimada, Mimata et al. 2012). In 
addition, Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ cells demonstrated 
enhanced β-catenin activity and migratory activity compared 
with Pdx-1-Cre;Trp53F/F;Cdh1F/+ cells. Thus, our study is the first 
to demonstrate the Smad4 loss-induced β-catenin activation in 
gastric cancer, and is consistent with a prior report that Smad4 
mediates canonical BMP signaling by repressing the transcription of 
β-catenin in SW480 colon cancer cells (Oliveira, Sousa et al. 
2009). Therefore, inhibition of β-catenin may be a converging 
node for the anti-metastatic signaling pathways driven by E-
cadherin and Smad4 in Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. 
Other possible mechanisms for the anti-metastatic role of Smad4 
may include suppression of proliferation, leading to proliferative 




Taken together, we conclude that loss of E-cadherin and Smad4 
cooperate to promote the metastatic progression of p53-null 
diffuse-type gastric carcinoma. By performing gastroduodenal 
epithelium-specific knockout of one allele of Cdh1 and both alleles 
of p53 and Smad4, which are frequently inactivated in human 
gastric cancers, we have created a genetically-engineered mouse 
model that develops distant metastasis. Gastric adenocarcinomas 
that formed in this genetic context, but not intestinal or mammary 
adenocarcinomas, lose E-cadherin expression and undergo EMT. 
These results closely recapitulate human diffuse-type gastric 
cancers, and sharpen our understanding of the interaction between 
E-cadherin and Smad4, two commonly inactivated tumor 
suppressors in gastric cancer. Additionally, the Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ will be extremely useful for 
preclinical studies given its similarities with human diffuse-type 










SCA-1 IS IDENTIFIED AS A POTENTIAL CANCER STEM CELL 
MARKER IN METASTATIC DERIVATIVES OF A MURINE GASTRIC 






There are no genetically defined murine gastric cancer cell lines or 
mouse models. A primary cell line (NCC-S1) was established from 
a gastric cancer that developed from a mouse deficient in Smad4, 
p53, and one copy of E-cadherin. NCC-S1 closely recapitulated, 
histologically and genetically, human diffuse-type gastric cancer. 
Furthermore, a cancer subpopulation of NCC-S1 cells was isolated 
from lung metastases that developed from heterotopic tumors 
transplanted into severe combined immunodeficiency mice. The 
metastasis derived cells, designated NCC-S1M, formed orthotopic 
tumors and exhibited a significant improvement in in vivo metastatic 
potential compared with the parental cell line, showing EMT 
features.  NCC-S1M cells demonstrated many features of cancer 
stem cells, including the ability to initiate tumor formation and 
chemoresistance. Importantly, Sca-1 was found to be more 
overerexpressed in NCC-S1M cells than NCC-S1 cells. Sca-1 
positive cells demonstrated increased ability to initiate tumor 
formation and in vivo chemoresistance than Sca-1 negative cells, 
showing upregulation of interleukin 1 signaling pathway. Genes 
overexpressed in Sca-1 highly positive NCC-S1 cells, compared 
with Sca-1 negative cells, clustered in 123 metastatic gastric 
cancer patients according to overall survival following 
cisplatin/fluorouracil chemotherapy. Taken together, we have 
identified Sca-1 as a murine gastric cancer stem cell marker using 






Gastric cancer is the fourth most common cancer and the second 
most common cause of cancer-related death in the world (Alberts, 
Cervantes et al. 2003). Despite the overall decline in gastric cancer 
prevalence, many patients who undergo surgical resection develop 
regional recurrences and distant metastasis and show anticancer 
drug resistance (Jemal, Siegel et al. 2008). It is postulated that 
tumors are composed of heterogenous cancer cells and that only a 
rare subpopulation of cells, known as cancer stem cells (CSC) is 
responsible for sustaining tumorigenesis and establishing the 
heterogeneity inherent in tumors (Visvader and Lindeman 2012). 
CSCs are promising for the development of anticancer drugs 
because it could explain resistance to chemotheraphy and eventual 
tumor relapse. The existence of a CSC in gastric cancer have been 
investigated in several reports and Takaishi et al identified putative 
cancer initiating cells within a CD44 positive cellular fraction in 
gastric cancer cells (Takaishi, Okumura et al. 2009). Although, 
several markers have proven useful for the isolation of CSCs in 
solid tumor, including CD133, Epcam, and CD44 (Visvader and 
Lindeman 2012), robust CSC markers have not been identified in 
human and mouse gastric cancers. 
In the scientific and pharmaceutical communities, there is a need 
for genetically defined, murine gastric cancer cell models that 




metastatic cell line models that can be used to study mechanisms of 
gastric cancer metastasis in immunocompetent mice. To address 
these issues, we have established primary cultured murine gastric 
cancer cell lines and their metastatic derivatives from Villin-
cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. These metastatic derivatives 
predictably form orthotopic tumors in syngeneic mice which 
predictably metastasize to liver and lung. In addition, these cells 
display several cancer stem cell-like features such as increased 
tumorigenic potential and chemoresistance. 
Importantly, our mRNA sequencing comparisons between these 
metastatic derivatives and parental cells identified Sca-1 as one of 
the overexpressed genes acquired during the metastasis process. 
Sca-1 is a marker of mouse hematopoietic stem cells, and is 
thought to be a cancer stem cell marker in murine breast cancer 
(Cohn, Kramerov et al. 1997; Treister, Sagi-Assif et al. 1998; Xin, 
Lawson et al. 2005; Grange, Lanzardo et al. 2008). It is upregulated 
on murine mammary cells undergoing carcinogen driven 
transformation, and in spheres generated from oncogene driven 
murine tumors (Li, Welm et al. 2003). Overexpression of Sca-1 is 
commonly associated with an aggressive phenotype in mouse 
tumors (Witz 2000). Sca-1 regulates mammary tumor development 
and cell migration, but its role in gastrointestinal carcinogenesis is 
not fully elucidated (Batts, Machado et al. 2011).  




high gastric cancer cells have cancer stem cell-like features. In 
addition, a gene expression signature for Sca-1 high cells was 
found to be associated with clinical chemoresistance. Sca-1 high 
cells showed upregulation of interleukin 1-related signaling. 
Collectively, we showed here for the first time Sca-1 might be 





Materials and Methods  
 
Mice 
B6.Cg-Tg(Vil-Cre)20Sy mice and FVB.129-Trp53tm1Brn mice 
(Jonkers, Meuwissen et al. 2001) were provided by the Mouse 
Models of Human Cancers Consortium repository at the NCI 
Frederick Cancer Research Center. B6.129-Cdh1tm2Kem/J mice were 
purchased from The Jackson Laboratory (Derksen, Liu et al. 2006). 
Pdx-1-Cre mice (B6.FVB-Tg(Ipf1-cre)1Tuv), originally 
generated by Dr. Lowy, were provided through the Mouse Models 
of Human Cancers Consortium (MMHCC) repository at the NCI 
Frederick Cancer Research Center. Conditional Smad4 knockout 
mice (Smad4F/F) on the Black Swiss and B6 and 129 backgrounds 
were generously provided by Dr. Chu-Xia Deng (NIH, Bethesda, 
MD) (Yang, Li et al. 2002). Compound conditional knockouts for 
Smad4, p53, and E-cadherin were bred with B6.Cg-Tg(Vil-
Cre)20Sy mice to delete transgenes in the gastrointestinal 
epithelium. Offspring mice were genotyped using polymerase chain 
reaction (PCR) assays on tail DNA. Genotyping primers were 
previously listed in Chapter 1. 
Severe combined immunodeficiency (SCID) mice were purchased 
from Orient Bio (Korea). Mice were anesthetized with isoflurane 
and sacrificed by cervical dislocation. Mouse studies were 




Committees of National Cancer Center of Korea and the National 
Cancer Institute, Bethesda, MD. 
  
Primary cell culture of NCC-S1 and NCC-S1M cells 
For primary culture, a gastric tumor arising in a Villin-
cre;Smad4F/F;Trp53F/F;Cdh1F/wt mouse was minced into small pieces 
that were digested with collagenase digestion for 30 min at 37˚C. 
Single tumor cells were seeded into plated on a 60-mm dish in 
RPMI 1640 media with 20% fetal bovine serum (FBS), 100U/ml 
penicillin and 0.1 mg/ml streptomycin in humidified incubator at 
37˚C in an atmosphere of 5% CO2. Initial passage was performed 
when heavy tumor cell growth was observed. Two tumor cell 
populations showing different morphology and growth rate were 
observed and each population was isolated. These cell lines were 
designated as NCC-S1 and NCC-S2, respectively. After 
establishment, the culture was maintained in RPMI 1640 with 10% 
FBS.  
To establish the metastatic variant cell line, 5 x 104 EpCam-
positive subpopulation of NCC-S1 cells were subcutaneously 
injected into SCID mice. After 80 days, mice were sacrificed and 
the lung metastasis of a mouse was transplanted to another SCID 
mice. After 55 days, the lung metastasis was primary cultured and 
this cell line was designated as NCC-S1M. All functional 






In vivo tumor cell injections 
 For orthotopic injection, SCID and syngenic mice were 
anesthetized using isoflurane. A small incision was made in the skin 
overlying the abdomen, and the stomach was exposed. 1 x 106 
tumor cells in 25 μl of RPMI and 25 μl of Matrigel (BD Bioscience) 
were injected into the serous side of the stomach using 0.5 ml 
insulin syringe. The necropsy was performed 4 weeks after 
injection. 
For splenic injection, SCID mice were anesthetized using 
isoflurane. A small incision was made in the skin overlying the 
abdomen, and the spleen was exposed. 0.5 x 106 tumor cells in 25 
μl of RPMI and 25 μl of Matrigel were injected into spleen. The 
necropsy was performed 3 weeks after injection. For tail vein 
injection, 0.1 x 106 tumor cells were injected into tail vein of SCID 
mice and the necropsy was performed 5 weeks after injection. 
 
Limiting dilution assay 
Tumor cells (106, 105, 104, and 103 cells) were suspended in 100 
μl of RPMI and 100 μl of Matrigel and were injected into the flank 
subcutaneous tissue of syngenic or SCID mice, using a 26-gauge 
needle and syringe. Data were analyzed using the Extreme Limiting 





In vitro chemoresistance ssay 
1 x 105 tumor cells were seeded into triplicate 12-well plate and 
cultured for 12 hours. After washing with fresh culture medium 
containing no antibiotics, cells were treated with 0.5, 1, 4, 6 μM 
cisplatin and 1, 10, 100, 1000 μM fluorouracil. 48 hours after drug 
treatment, 200 μl of MTT solution (5mg/ml in PBS) was added to 
each well in 1 ml of media. Formazane formation was terminated 
after 2 hours by removing the MTT solution. 500 μl DMSO was 
added into each well to dissolve the precipitation. The absorbance 
was detected at 570 nm with a Microplate Reader.  
 
In vivo chemoresistance assay 
Fluorouracil (5-Fu) and Cisplatin, two anticancer drugs, were 
purchased from Sigma Aldrich (Buchs, Switzerland). The drugs 
were dissolved in 10% DMSO. The mice were intraperitoneally 
injected with 5-Fu (25 mg/kg) once daily for four days. Cisplatin 
(5mg/kg) was administered at the last day of 5-Fu treatment.  
Sca-1 high- and negative-sorted tumor cells (5 x 105 cells in 
100 µl of serum-free RPMI) were mixed with equal volumes of 
Matrigel (BD Biosciences, Bedford, MA) and injected into the 
subcutaneous flank tissue of the nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice. When the tumors reached 




per drug-treated group. The responses of the tumors to the drugs 
were evaluated using percent treated/control (% T/C), as 
determined by dividing the median tumor volume of the treatment 
group (T) by that of the negative control group (C) on the day of 
measurement. If a tumor regressed, % T/C was defined by the 
negative of the percentage of decrease in the median tumor volume 
of the treatment group (T) relative to the baseline volume on the 
day of measurement. 
 
Quantitative real-time RT-PCR (QRT-PCR)   
Total RNA was isolated from mouse gastric cancer cells using 
AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. Total RNA (0.3μg) 
was reverse transcribed using random hexamers and amfiRivertII 
Reverse Transcriptase (GenDEPOT, Barker, TX) according to the 
manufacturer’s standard protocols. PCR reactions were performed 
on a Roche LC480 (Roche Diagnostics, Penzberg, Germany) using 5 
μl of 2× QuantiTect SYBR Green PCR Master Mix (Qiagen), 400 
nM of each primer, and 2μl of cDNA sample which was diluted 1:5 
in water in a total volume of 10μl. Cycling conditions were as 
follows: 15 min at 95°C, followed by 55 cycles each consisting of 20 
s at 94°C, 20 s at 57°C and 20 s at 72°C. Data were analyzed using 
the LC480 software (Roche Diagnostics). QRT-PCR primers were 




calculate relative changes. 
 
Immunohistochemistry and immunofluorescence  
The excised gastric tumor was fixed in neutral buffered 10% 
formalin, processed by standard methods and embedded in paraffin. 
5-μm cross sections were cut and then stained with H&E for 
histopathological examination. The ABC method (Vectastain Elite 
ABC kit and Vectastain M.O.M. kit, Vector Laboratories) was used 
for immunohistochemical detection of c-myc, p53, Smad4 and ki-
67. The following antibodies were used in this study; rabbit 
polyclonal anti E-cadherin antibody (1:200; Cell Signaling, #3195), 
rabbit polyclonal anti c-Myc antibody (1:50; Abcam, ab32072), 
rabbit polyclonal anti p53 antibody (1:100; Santa Cruz, sc-6243), 
mouse monoclonal anti Smad4 (1:50; sc-7966) and rabbit 
polyclonal anti Ki-67 (1:200; Abcam, ab15580). The slides were 
subjected to colorimetri detection with ImmPact DAB substrate 
(Vector Laboratories, SK-4105). The slides were counterstained 
with Mayer’s hematoxylin for 10 seconds. Negative controls were 
performed by omitting the primary antibody and substitution with 
diluent.  
 
Western blot anaylsis 
Cells were collected 48 hours after seeding 3 x 105 cells in 100 




(Thermo Fisher Scientific, Hudson, NH, U.S.A) supplemented with 
protease inhibitors. After removal of cellular debris, protein 
concentration was quantitated by using a BCA reagent kit (Thermo 
Fisher Scientific, Hudson, NH, U.S.A) according to manufacturer’s 
instruction. Protein sample was prepared by making a 3 in 4 dilution 
with 4x Laemmli sample buffer (250 mM Tris-HCl (pH 6.8), 4% 
SDS, 40% glycerol, 0.05% bromphenol blue, 4% 2-mercaptoethanol) 
and boiling for 5 minute. Equal amounts of protein were separated 
on SDS-polyacrylamide gel and transferred onto nitrocellulose 
membrane by electrophoresis and blotting apparatus (Bio-Rad, 
Hercules, CA, U.S.A). The proteins were probed with the relevant 
primary antibodies and horseradish peroxidase (HRP)-conjugated 
secondary antibodies at the recommended dilutions. The rabbit 
polyclonal anti E-cadherin antibody (1:1000; Cell Signaling, 
#3195), rabbit polyclonal anti c-Myc antibody (1:1000; Abcam, 
ab32072), rabbit polyclonal anti p53 antibody (1:1000; Santa Cruz, 
sc-6243), mouse monoclonal anti Smad4 (1:1000; sc-7966), 
rabbit monoclonal anti JNK1/2/3 antibody (1:1000; Abcam, 
ab124956), rabbit monoclonal anti phosphor-IkBa antibody (1:1000, 
Cell signaling, #2859), and rabbit monoclonal anti phosphor-p44/42 
MAPK (Erk1/2) (1:1000, Cell signaling, #4370), and were applied. 
Immunodetection were performed. by using an enhanced 
chemiluminescence (ECL) detection kit (Thermo Fisher Scientific, 





Flow cytometry (FACS) analysis and fluorescence-activated cell 
sorting 
Tumor cells were detached with trypsin and stained with anti-
mouse Ly6a PE (sca-1, 1:800; BD pharminogen, 553336), anti-
mouse CD133 PE (1:300; ebioscience, 12-1331-82) and anti-
mouse Epcam PE (1:200; ebioscience, 12-5791-82) for 30 
minutes at 4°C in the dark room with gentle agitation. The stained 
cells were resuspended with FACS sorting buffer (1 mM EDTA, pH 
7.0 25 mM HEPES, 1% FBS,Ca2+ and Mg2+ free PBS). The cells 
were sorted on an Aria cell sorter (BD biosciences, San Jose, CA). 
 
In vivo tumor cell injection after IL-1β treatment 
 NCC-S1 cells were seeded on 6 well plates. 12 hours after 
seeding, the cells were treated with 25 ng/ml recombinant mouse 
IL-1β (R&D systems, 401-ML-025) in serum free RPMI 1640. 
24 hours after the treatment, tumor cells were detached with 
trypsin and 0.5 x 106 tumor cells in 100 μl of RPMI and 100 μl of 
Matrigel were injected into the flank subcutaneous tissue of SCID 
mice. 
 
Measurement of β-catenin activity 
Primary cultured cells (2.5 x 104 cell/well) were plated in 24 wells 




with the TCF/LEF reporter plasmid according to the protocol of the 
manufacturer using Lipofectamine 2000 transfection reagent (Life 
Technologies). 24 hours after the transfection, Opti-MEM medium 
was changed to RPMI 1640 containing 10% FBS. The cells were 
allowed to grow for one more day and luciferase assays were 
carried out using the dual luciferase reporter assay system 
(Promega, Madison, WI) according to the manufacturer’s protocol. 
Light emission was quantified with a Victor 3 1420 luminescence 
microplate reader (Perkin-Elmer, Waltham, MA). The signals were 
normalized for transfection efficiency to the internal Renilla control. 
 
RNA sequencing and DNA microarray 
Total RNAs (1μg), isolated from NCC-S1 and NCC-S1M cells, 
were subjected to RNA sequencing using HiSeq2000 sequencer and 
TruSeq protocol, according to the manufacturer’s recommendation 
(Illumina Hayward, CA). Quantile-normalized FPKM (fragments per 
kilobase of exon per million fragments mapped) was used as the 
expression level of each gene. 1 μg of total RNAs, isolated from 
NCC-S1 cells and normal epithelial mucosa, were subjected to 
Mouse Gene 1.0 ST array, according to the manufacturer’s 
recommendation (Affymetrix, Sanat Clara, CA). BRB-ArrayTools 
(ver 4.1) was used for gene set comparison and hierarchical 
clustering analyses. After gene centering, average linkage 




a distance metric. Survival difference was evaluated by a log rank 
test using SAS software (proc lifetest, Cary, NC). The Sca-1 
signature was annotated using DAVID functional annotation tool 
(http://david.abcc.ncifcrf.gov/).  
 
CGH array analyses 
CGH array analyses were performed using Mouse GE 4x44K v2 
Microarrays and 0.5 µg of tumor genomic DNA samples and the 
same amount of tail genomic DNA of each mouse, according to the 
manufacturer’s recommendation (Agilent Technologies, Santa Clara, 
CA). Using Agilent's CGH Analytics software, the data were 
mapped to mm8 mouse genome and analyzed using the ADM-2 
algorithm (Threshold of ADM-2: 6.0; Centralization: ON; Fuzzy 
Zero: ON; Aberration Filters: ON (minProbes = 3 AND 
minAvgAbsLogRatio = 0.25 AND maxAberrations = 10000000 
AND percentPenetrance = 0)). An average tumor/normal log2 ratio 
> 0.5 for 5 or more consecutive probes in a genomic locus was 






Establishment of primary cultured NCC-S1 cells recapitulating 
human diffuse-type gastric cancer 
One of 45 Villin-cre;Smad4F/F;Trp53F/F;Cdh1F/wt mice developed 
spontaneous gastric adenocarcinoma in the glandular stomach at 28 
weeks of age (Fig 1A). Histology of the primary tumor 
recapitulated human diffuse-type gastric carcinoma (Fig 1B and 
1C). Immunohistochemisty demonstrated that the tumor lost 
expression of Smad4 and Trp53 as predicted (Fig 1D). The gastric 
adenocarcinoma showed high Ki-67 proliferative index and 
overexpression of Myc oncogene (Fig 1E and 1F).  
NCC-S1 was primarily cultured and established from this gastric 
cancer. In vitro morphology of the cell lines was epithelial cell type 
(Fig 2A). Western blotting analyses indicated that NCC-S1 showed 
overexpression of Myc as observed in the primary gastric tumor 
(Fig 2B). Array-comparative genomic hybridization revealed copy 
number gains of chromosomes 19q and 15q harboring Myc (log 
ratio, 0.92 and 0.55, respectively, data not shown). A survey of key 
regulators of G1/S transition revealed significant induction of Cyclin 
D1 with down regulation of p21 (Fig 2B). p21 is one of target genes 
for TGF-β pathway and tightly controlled by p53 (Elston and 
Inman 2012). p21 acts to induce a G1 arrest via the inhibition of 




Gene expression profiles of NCC-S1, as identified by RNA 
sequencing analysis, showed significant overlaps with human gastric 
cancers. There were 3,742 overexpressed and 1,378 
underexpressed genes in NCC-S1 cells compared with normal 
gastric epithelium (by > 3-fold). Both overexpressed genes (4,322 
Affymetrix probe sets) and underexpressed genes (1,241 
Affymetrix probe sets) significantly overlapped with genes 
differentially expressed between 123 gastric cancer patients and 21 
normal tissue samples (LS p values, 0.043 and < 0.001, 
respectively). These data indicate that NCC-S1 recapitulated 






Fig 1. (A) Gross findings of a gastric cancer, an ulceroinfiltrative 
mass in the antral mucosa, arising in Villin-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice. (B and C) Histopathological 
findings of the gastric cancer. H&E. (D) Immunohistochemistry for 
the confirmation of loss of Smad4 and p53 in the gastric cancer. (E) 












Fig 2. (A) In vitro morphology of NCC-S1. (B) Western blot 
analysis showing upregulated expression of Myc and Cyclin D1 and 







Establishment of metastatic variant NCC-S1M  
A cancer subpopulation was then isolated from lung metastatic foci 
that developed from heterotopic tumors of NCC-S1cells on SCID 
mouse. This metastatic derivative, designated as NCC-S1M, grew 
like mesenchymal cells in terms of in vitro morphology (Fig 3A). 
Consistent with mesenchymal morphology, E-cadherin protein was 
down-regulated in NCC-S1M cells compared to NCC-S1 (Fig 3Bi), 
but the Cdh1 promoter hypermethylation was not identified (data 
not shown). Although expression of Vimentin, a widely used 
epithelial to mesenchymal transition (EMT) marker, did not change 
in NCC-S1M compared to NCC-S1 cells, this marker is not suitable 
for evaluation of the EMTs in NCC-S1M cells because NCC-S1 
cells already exhibited strong expression of Vimentin (Fig 3Bi). 
mRNA expression of EMT regulators was elevated in NCC-S1 M 
cells compared to NCC-S1 cells (Fig 3Bii). In addition, NCC-S1M 
cells showed higher activity of a Wnt signaling reporter than that of 
NCC-S1 cells (Fig 3Ciii). NCC-S1M cells consistently developed 
lung metastasis after the heterotopic, splenic, and tail vein injection 











Fig 3. (A) In vitro morphology of NCC-S1M. (B) ). (Bi) Western 
blot analyses showing down-regulated E-cadherin expression in 
NCC-S1M. (Bii) The mRNA expression of mesenchymal markers 
and EMT regulators of NCC-S1M as compared with that of NCC-
S1. (Biii) Increased β-catenin reporter activity of NCC-S1M 




Table 1. Frequency of gross or microscopic metastasis of NCC-S1 















0 / 8 
(0%) 
5 / 5 
(100%) 
0 / 5 
(0%) 
5 / 5 
(100%) 
0 / 5 
(0%) 
4 / 5 
(80%) 
 
1According to the necropsy findings 4 weeks after injection 
2According to the necropsy findings 3 weeks after injection  





NCC-S1M showed uniform cancer stem cell-like characteristics. 
NCC-S1M proliferated much more rapidly than parental S1cells in 
vivo (Fig 4Ai). All of SCID mice harboring NCC-S1M tumors 
showed lung metastasis when the volume of the primary tumor in 
the flank reached 1,700 mm3, while NCC-S1 didn’t showed any 
lung metastasis at the same volumes (Fig 4Aii). NCC-S1M cells 
overexpressed EpCam and CD133, putative cancer stem cell 
markers (Fig 4B). NCC-S1M cells also demonstrated the increased 
tumorigenic potential in syngeneic mice (Table 2). In addition, 
NCC-S1M cells were more resistant to fluorouracil and cisplatin 
than NCC-S1 cells (Fig 5, cisplatin IC50 of S1 and S1M = 0.97 μM 
and 2.10 μM, fluorouracil IC50 of S1 and S1M = 1.60 μM and 3.50 
μM). In addition, these results show that this metastatic variant cell 










Fig 4. (A) In vivo growth for NCC-S1M and NCC-S1. (B) FACS 
findings demonstrating overexpression of EpCam and CD-133 in 




 Table 2. Comparison of tumorigenic potential between NCC-S1 
and NCC-S1M in syngenic mice. 
   
Cell  Cell dose 
No. mice with 
tumors (%) 
P 
    
NCC-S1M  1 X 106 7 / 7 (100) 
 
 
1 X 105 6 / 6 (33.3) 
 
 
1 X 104 4 / 6 (16.7) 
 
 
1 X 103 3 / 6 (16.7) 
 
   
<0.001 
NCC-S1  1 X 106 4 / 7 (14.3) 
 
 
1 X 105 2 / 6 (0) 
 
 
1 X 104 1 / 6 (0) 
 
 
1 X 103 0 / 6 (0) 
 
   
  








    
 
Fig 5. Decreased IC50 for fluorouracil (A) and cisplatin (B) in 






Sca-1 was upregulated in NCC-S1M cells and Sca-1 postive cells 
showed cancer stem cell-like characteristics 
Given that NCC-S1M cells showed cancer stem cell-like features, 
it was hypothesized that gene expression profiling of these cells 
may provide clues for the identification of putative stem cell 
markers in our cell line model. An mRNA sequencing comparison 
between NCC-S1M and NCC-S1 identified Sca-1 as one of the 
most significantly overexpressed genes. Overexpression of Sca-1 
protein in NCC-S1M cells was validated using FACS analyses (Fig 
6A) and immunofluorescence (Fig 6B). FACS-sorted Sca-1 high 
population was compared with Sca-1 negative population for the 
tumorigenic potential using the limiting dilution assay. After 3 
weeks, SCID mice injected with 105 Sca-1 high NCC-S1 and NCC-
S2 cells formed subcutaneous tumors, while mice injected with the 
same number of Sca-1 negative cells did not. After 8 weeks, there 
was significant difference in tumors formed according to the Sca-1 
(Table 3). Once formed, Sca-1 high cells also grew much faster in 
vivo (data not shown). Sca-1 FACS analysis using Sca-1 high 
cell-forming tumors showed that they consisted of tumor cells with 
a wide range of expression pattern of Sca-1 similar to that of 
original cell line (data not shown). The limiting dilution assay using 
two primary gastric cancer cell lines from gastric cancers arising in 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice also demonstrated that 




Sca-1 negative population as observed in NCC-S1 and NCC-S2 
(Table 4). In addition, Sca-1 high cell-forming tumors showed 
higher rates of drug resistance than Sca-1 negative cell-forming 












Fig 6. (A) Sca-1 FACS finding for NCC-S1M and S1 cells and (B) 




Table 3. Limiting dilution assays for NCC-S1 and S2 in Nude mice 
according to Sca-1 expression, measured 8 weeks after injection 
 
Cell  Cell dose 





   
Sca-1 high  1 X 105  5 / 5 (100.0)  
 
 
1 X 104  5 / 5 (100.0)  
 
 
1 X 103  4 / 5 (80.0)  
 
   
<0.001  
Sca-1 negative 1 X 105  4 / 5 (80.0)                
 
 
1 X 104  4 / 5 (80.0)  
 
  1 X 103  2 / 5 (40.0)    
    
    
NCC-S2  
   
Sca-1 high 1 X 105  5 / 5 (100.0)  
 
 
1 X 104  5 / 5 (100.0)  
 
 
1 X 103  4 / 5 (80.0)  
 
   
<0.001  
Sca-1 Low  1 X 105  5 / 5 (100.0)                
 
 
1 X 104  4 / 5 (80.0)  
 
  1 X 103  0 / 5 (40.0)    




Table 4. Limiting dilution assays for Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ gastric cancer cell lines in Nude mice 
according to Sca-1 expression, measured 8 weeks after injection 
 
Cell  Cell dose 
Number of mice with tumors 
(%) 
P-value 
Cell line 1  
   
 
1 X 105  5 / 5 (100.0)  
 
High  1 X 104  5 / 5 (100.0)  
 
 
1 X 103  3 / 5 (60.0)  
 
   
<0.001  
 
1 X 105  5 / 5 (100.0)  
 
Negative  1 X 104  3 / 5 (60.0)  
 
 
1 X 103  0 / 5 (0.0)  
 
Cell line 2 
   
 
1 X 105  5 / 5 (80.0)  
 
High  1 X 104  4 / 5 (0.0)  
 
 
1 X 103  4 / 5 (0.0)  
 
   
<0.001  
 
1 X 105  5 / 5 (0.0)  
 
Negative 1 X 104  4 / 5 (0.0)  
 
 











Fig 7. Gastric cancer cells with high Sca-1 expression showed 
higher In vivo chemoresistance to 5-Fu (25 mg/kg) and Cisplatin 
(5 mg/kg) combination treatment on SCID mice than Sca-1 




Sca-1 gene expression signature predicts survival following 
chemotherapy  
According to the DNA microarray analysis, 85 genes were 
overexpressed by greater than 1.5-fold in Sca-1 high NCC-S1 
cells compared with Sca-1 negative NCC-S1 cells (Table 5). 
These 85 genes overexpressed in Sca-1 high cells were 
designated as the Sca-1 signature. Interestingly, CD133, a potential 
cancer stem cell marker in gastric cancer, was included in these 85 
genes (Fukamachi, Shimada et al. 2011; Qiao and Gumucio 2011). 
Fscn1 (Chen, Yang et al. 2010; Sun, He et al. 2011), Lox (El-Haibi, 
Bell et al. 2012) and Tnc (Oskarsson, Acharyya et al. 2011), known 
to be critical for metastasis, were included among these 85 genes. 
Nestin, a neural stem cell marker, which was also known to promote 
metastasis, was also included (Lendahl, Zimmerman et al. 1990; 
Matsuda, Naito et al. 2011). Embryonic stem cell markers, such as 
SOX9 (Matheu, Collado et al. 2012), and others involved in the stem 
cell niche, such as Cxcl7 (Liu, Ginestier et al. 2011), were also 
included in the Sca-1 signature. As shown in Table 5, most of 
these 85 genes were also overexpressed in NCC-S1M cells 
compared with Sca-1 negative NCC-S1 cells.  
Because Sca-1 does not have human homologs, human homologs 
of these 85 mouse genes in the Sca-1 signature (88 Affymetrix 
probe sets) were evaluated for clinical relevance. Using these 88 




was performed on DNA microarray data for pretreatment biopsy 
samples collected from gastric cancer patients who were treated 
with cisplatin/fluorouracil chemotherapy (Kim, Choi et al. 2012). 
The Sca-1 signature clustered 123 patients into 2 subsets (Fig 8A). 
Patients who overexpressed genes in the Sca-1 signature had 
significantly shorter overall survival following cisplatin/fluorouracil 
chemotherapy compared with those who underexpressed these 
genes {7.6 months [95% confidence interval (CI), 6.1-9.2] vs 11.9 
months (95% CI, 8.1-16.8); log-rank p value = 0.005; hazards 
ratio = 1.7 (95% CI, 1.2-2.5)} (Fig 8B), while 2 patient subsets 
clustered using all Affymetrix probe sets were not different in 
overall survival (data not shown). Ifitm3, Fscn1, Wnt7a, and Cldn6 
were representative genes in the Sca-1 signature that were 
associated with poor survival following chemotherapy. Thus, 









Fig 8. (A) A hierarchical clustering dendrogram for pretreatment 
biopsy samples of chemotherapy-treated gastric cancer patients, 
which was generated using genes overexpressed in Sca-1 high S1 
cells (Sca-1 signature) (B) Overall survival of 2 clusters generated 
by (A). Patients who overexpressed the Sca-1 signature had 




Table 5. Sca-1 signature (shown in the order of decreasing fold 
change) 
 
Gene Sca-1 Negative Sca-1 High NCC-S1M 
Ly6c1 1213 4979 9587 
Ifitm3 449 1805 11824 
Vmn1r93 53 185 79 
Dcn 299 1022 1064 
Ly6a 3020 10046 14630 
Ly6c2 652 2094 4017 
Rhox4e 33 104 34 
2310007B03Rik 515 1480 537 
Rhox4a 52 135 70 
Serpine2 475 1208 3138 
Fscn1 739 1853 5673 
C87414 28 69 41 
Rpl21 63 153 106 
Fstl1 704 1673 4448 
Prrx1 324 736 5700 
Fgf7 459 992 1095 
D5Ertd577e 29 62 37 
Lox 1212 2550 2948 
Cldn2 314 637 174 
Nes 394 778 1297 
Pcolce 1739 3354 9013 
Sox9 709 1367 1881 
C1s 91 175 340 
Prom1 359 676 1355 
6330406I15Rik 197 370 1598 
Igf2bp3 257 483 477 
Enpp2 447 834 424 
Lcn2 418 775 1168 
Tnc 579 1063 2495 




Gjc1 412 748 887 
Ccbe1 634 1147 3342 
Pdzrn3 267 476 541 
Thbs1 2505 4427 10678 
5730471H19Rik 760 1340 2392 
Tmem173 389 683 3525 
Vmn2r43 85 149 118 
Sox11 347 607 266 
AI451617 75 130 950 
Gprc5c 405 700 272 
Lrrk2 286 489 293 
Angpt1 116 197 740 
Ott 236 399 329 
Ppap2b 833 1398 2934 
Acan 488 817 1835 
Hmcn1 117 195 420 
Wnt7a 353 585 1243 
Grasp 695 1145 2104 
Ebf1 230 379 811 
Plac9 237 390 444 
Ccl7 517 843 3220 
Xlr4b 148 239 142 
Pmp22 2345 3783 5895 
Gpr176 1113 1792 2349 
Saa3 183 294 458 
Igfbp4 888 1425 8755 
2610528A11Rik 1411 2252 431 
C3 3061 4874 7550 
Cldn6 4456 7067 6177 
Cda 1187 1878 2540 




Amd1 142 224 106 
Masp1 493 776 3624 
Pramel3 108 169 96 
Osmr 1303 2041 3855 
Tgm2 1378 2151 1671 
Sema6a 445 694 1247 
Cmbl 409 638 218 
Fndc4 580 901 1555 
Nox4 169 261 855 
Gm4907 137 211 154 
Il1rl1 485 748 11874 
Plxdc2 377 579 3891 
Pcdh18 567 871 571 
Hmgb1 466 713 691 
Ifi203 231 354 911 
Sdc3 476 726 606 
Olfr1331 110 167 152 
Speer4d 129 195 106 
Olfr963 124 188 116 
Sirpa 807 1222 2081 
Il1r1 554 837 1140 
Rcn1 762 1149 2212 
EG381936 72 109 69 





Upregulated Interleukin-1 signaling pathway in Sca-1 postive cells 
Because DAVID functional annotation chart analyses on the Sca-1 
signature demonstrated that Sca-1 high cells exhibited accentuated 
inflammatory response associated with interleukin 1 signaling such 
as higher expression of interleukin 1 receptor type 1 (IL1R1) than 
Sca-1 negative cells (Table 6), we hypothesized that Sca-1 high 
cancer cells acquired the cancer stem cell-like properties via 
activation of interleukin 1 pathway.  
Actually, Sca-1 high cells consistently showed higher gene 
expression levels of interleukin 1-related genes such as IL1R1, 
IL1RL1, and IL1RAP compared to Sca-1 negative cells as NCC-
S1M cells did compared to NCC-S1 cells (Fig 9). Western blot 
analysis demonstrated that Sca-1 high cells showed upregulated 
JNK and higher expression of phosphorylated c-Jun and Bcl-xl 
than Sca-1 negative cells as observed in NCC-S1M cells (Fig 10). 
JNK, which could be activated by interleukin 1, phosphorylates and 
regulates the activity of proto-oncogene c-Jun (Davis 2000). Bcl-
xL protects against apoptotic cell death and results in survival of 
cancer cells, thus confers resistance to multiple chemotherapy 
agents (Minn, Rudin et al. 1995). The activity of Bcl-xL could be 
regulated by JNK (Liu and Lin 2005). 
To determine whether Interleukin 1 signaling pathway plays an 
important roles in tumorigenesis, we activated Interleukin 1 




treated by IL-1β showed enhanced tumorigenic potential 
compared to untreated NCC-S1 cells (Fig 11A). These cells also 
enhanced JNK pathway and Bcl-xL level (Fig 11B). FACS analysis 
demonstrated that IL-1β treatment on NCC-S1 cells didn’t 







A                          B 
 
 








Fig 9. mRNA expression of interleukin 1-related genes (IL1R1, 
IL1RL1, and IL1RAP) in NCC-S1M cells compared to NCC-S1 
cells (A), in Sca-1 high NCC-S1 cells compared to Sca-1 negative 
NCC-S1 cells (B), in Sca-1 high NCC-S2 cells compared to Sca-
1 negative NCC-S2 cells (C), and in Sca-1 high Pdx1-cre gastric 






Fig 10. Western blot analyses showing the overexpression of JNK, 
phospholylated c-Jun, and Bcl-xL in NCC-S1M cells compared to 
NCC-S1 cells and in Sca-1 high gastric cancer cells compared to 








Fig 11. (A) Enhanced tumorigenic potential in NCC-S1 cells treated 
by IL-1β in subcutaneously tumor cell-injected SCID mice. (B) 
Western blot analyses showing upregulated expression of JNK, 
phospholylated c-Jun, and Bcl-xL in IL-1β-treated NCC-S1 




Table 6. DAVID functional annotation chart analyses on the genes 
upregulated by >1.5-fold in Sca-1 high S1cells (Sca-1 signature) 
 









IL1R1, TMEM173, MASP1, IL1RL1, 










CCBE1, TGM2, PRRX1, ANGPT1, 
LOX, PPAP2B, GJC1 
GO:0032103~positive 
regulation of response to 
external stimulus 




CCBE1, TGM2, PRRX1, ANGPT1, 
LOX, PPAP2B, GJC1 
GO:0048584~positive 
regulation of response to 
stimulus 
0.0010  










IL1R1, TMEM173, MASP1, IL1RL1, 
C3, ENPP2, C1S, CCL7 
GO:0002526~acute 
inflammatory response 
0.0045  MASP1, C3, SAA3, C1S 
GO:0022612~gland 
morphogenesis 
0.0050  FGF7, TNC, TGM2, SOX9 
GO:0007155~cell adhesion 0.0079  
CLDN6, TNC, ACAN, CLDN2, THBS1, 




CLDN6, TNC, ACAN, CLDN2, THBS1, 
SOX9, SIRPA, PCDH18 
GO:0032101~regulation of 
response to external stimulus 




CCBE1, TGM2, PRRX1, ANGPT1, 
GJC1 
GO:0002541~activation of 
plasma proteins involved  
0.0096  MASP1, C3, C1S 
in acute 
inflammatory response   
GO:0006956~complement 
activation 














0.0208  MASP1, C3, C1S 
GO:0042127~regulation of cell 
proliferation 
0.0228  




0.0235  TNC, ACAN, LOX, WNT7A 
GO:0060638~mesenchymal-
epithelial cell signaling 
0.0245  FGF7, TNC 
GO:0051605~protein 
maturation by peptide bond 
cleavage 
0.0294  MASP1, C3, C1S 
GO:0051216~cartilage 
development 
0.0410  ACAN, PRRX1, SOX9 
GO:0050921~positive 
regulation of chemotaxis 
0.0444  HMGB1, THBS1 
GO:0048732~gland 
development 
0.0475  FGF7, TNC, TGM2, SOX9 
GO:0048520~positive 
regulation of behavior 
0.0484  HMGB1, THBS1 
GO:0050920~regulation of 
chemotaxis 
0.0484  HMGB1, THBS1 
GO:0002253~activation of 
immune response 







There are only a few murine gastric cancer cell lines available in 
the scientific community, neither of which is genetically defined 
because tumors were carcinogen-induced. Several genetically 
engineered mouse models for gastric cancer have been reported, 
these models have been generated in the lineage of parietal cells 
using K14 and Atb6 promoters (Wang, Dangler et al. 2000; Oshima, 
Matsunaga et al. 2006; Shimada, Mimata et al. 2012), from which no 
human gastric cancer ever originate. On the other hand, we have 
developed a spontaneous mouse gastric cancer deficient in Smad4 
and p53, which represent most frequently mutated genes/pathways 
in gastric cancer (Wang, Kim et al. 2007), using Villin-cre mice. 
The Villin promoter is active in quiescent cells in the antrum until 
E16 (Qiao, Ziel et al. 2007). In this regard, this mouse gastric 
cancer of ductal origin uniquely recapitulates human gastric 
adenocarcinomas from both histological and molecular perspectives.  
Only one of 45 Villin-cre;Smad4F/F;Trp53F/F;Cdh1F/wt mice have 
developed the gastric cancer primarily because they had obstructive 
intestinal tumors at an early age. Even so, we were able to establish 
one cell line, NCC-S1, primarily cultured from the Villin-
cre;Smad4F/F;Trp53F/F;Cdh1F/wt gastric cancer. Significant overlap 
between human and mouse gastric cancer signatures was observed 




gastric cancer, was also found to be amplified in our cells (data not 
shown). NCC-S1M cells were primarily cultured from lung 
metastases of NCC-S1 cells. Interestingly, NCC-S1M cells showed 
EMT phenotype including morphology and molecular perspectives, 
showing enhanced Wnt signaling. EMT is crucially involved in 
cancer metastasis and Wnt signaling has been linked to the process 
of EMT (Vincan and Barker 2008; Kahlert, Maciaczyk et al. 2012). 
Thus, EMT features of NCC-S1M are partially explainable by the 
EMTs. 
NCC-S1M cells consistently developed lung metastases more 
rapidly than parental clones. Moreover, NCC-S1M cells provide an 
orthotopic gastric cancer model that predictably metastasizes to 
lung and liver. For the first time to our knowledge, these cells can 
serve as unique models to evaluate the metastatic potential of 
gastric cancer. In addition, NCC-S1M cells are very useful to test 
efficacy and toxicity of immunotherapeutic agents because this cell 
line readily formed tumor in syngeneic host mice. Actually anti-4-
1BB mAb, novel immunotherapeutic agent, significantly suppressed 
the growth of NCC-S1M compared with controls. 
NCC-S1M cells demonstrate cancer stem cell-like features such 
as increased tumorigenicity, metastasis, and chemoresistance. Sca-
1 was found to be one of the most highly upregulated genes in 
NCC-S1M cells. Our findings are consistent with data in the 




members are commonly associated with an aggressive tumor 
phenotype (Cohn, Kramerov et al. 1997; Treister, Sagi-Assif et al. 
1998; Witz 2000; Li, Welm et al. 2003; Xin, Lawson et al. 2005; 
Grange, Lanzardo et al. 2008; Batts, Machado et al. 2011). Sca-1 is 
associated with increased tumorigenicity or metastasis in breast or 
prostate cancers but not in gastrointestinal tract cancers. Although 
Sca-1 is murine-specific, our gastric cancer patient database 
indicates that the Ly6 gene family (8q24.3) is frequently amplified 
(9%), and associated with poor response to cisplatin/fluorouracil 
chemotherapy (hazard ratios of LY6E and LY6D=1.2 and 1.2; 
p=0.025 and 0.042, respectively). Moreover, we observed the 
similar association between the poor clinical response to 
chemotherapy and the high expression of Sca-1 gene expression 
signature (Fig 4D). In addition, several putative stem cell markers 
such as CD133 and SOX9 were included in the Sca-1 gene 
expression signature (Table 5).  
Sca-1 high populations in our gastric cancer cell lines showed 
higher tumorigenic potential and chemoresistance. FACS analysis 
demonstrated that Sca-1 high population comprises about 5% of 
our primary gastric cancers arising in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice and Sca-1 high cell-forming 
tumors consisted of tumor cells with a wide range of expression 




shown). Collectively, these results suggest that Sca-1 might be a 
murine gastric cancer stem cell marker. 
In normal mammary cells, the mechanism of action of Sca-1 
involves the inhibition of TGF-β signal transduction pathway 
(Upadhyay, Yin et al. 2011). Because our Smad4-null cells are 
deficient in the TGF-β pathway, other signal transduction 
pathways may play important roles in Sca-1 high cells. 
Interestingly, the DNA microarray analysis demonstrated that the 
Sca-1 signature is significantly enriched in genes involved in the 
immune system and immune response, especially upregulation of 
interleukin 1 signaling-related genes such as IL1R1 and IL1RL1. In 
addition, Sca-1 high cells consistently showed higher gene 
expression levels of IL1R1, IL1RL1, and IL1RAP compared to Sca-
1 negative cells and IL-1β-treated NCC-S1 cells showed 
enhanced tumorigenic potential compared to untreated NCC-S1 
cells. This finding provides the possibility that cancer stem cell like 
phenotype in Sca-1 high cells might be explained by enhanced 
interleukin 1 signaling pathway. Inflammatory cytokines play a key 
role in malignant progression of various cancers (Germano, 
Allavena et al. 2008). Although dual roles for activated interleukin 1 
signaling pathway have been proposed, activation of this pathway 
been associated with a aggressive tumor phenotype such as growth, 
invasion, and metastasis in several types of mouse or human 




2006). Interleukin 1 gene cluster polymorphisms suspected of 
enhancing production of interleukin 1 beta are associated with an 
increased risk of gastric cancer (El-Omar, Carrington et al. 2000). 
Recent study revealed the effects of IL-1beta on the promotion of 
stemness such as increased tumorigenic potential and drug 
resistance in glioma and colon cancer cells (Li, Wang et al. 2012; 
Wang, Liu et al. 2012). 
Western blot analysis showed that Sca-1 high cells up-regulated 
JNK, a mitogen-activated protein kinase (MAPK) family member, 
compared to Sca-1 negative cells. Increased JNK expression in 
Sca-1 high cells might be associated with enhanced interleukin 1 
pathway because its enzymatic activity is induced in response to 
diverse stimuli including cytokine such as interleukin 1 and tumor 
necrosis factor (TNF) (Li, Commane et al. 2001; Seki, Brenner et al. 
2012). Expectedly, phosphorylated c-jun, a representative target 
of JNKs (Seki, Brenner et al. 2012), was overexpressed in Sca-1 
high cells. Although roles of JNK in cancer are unclear, several 
mouse cancer models revealed the oncogenic roles in 
gastrointestinal cancers (Sakurai, Maeda et al. 2006; Shibata, 
Maeda et al. 2008). Mice lacking JNK1 exhibited a marked decrease 
in gastric carcinogenesis induced by N-methyl-N-nitrosourea 
compared to their wild-type counterparts (Shibata, Maeda et al. 
2008). Bcl-xL, antiapoptotic protein, also increased in Sca-1 high 




(Minn, Rudin et al. 1995) and multiple kinases, including JNKs, 
mediate phosphorylation of Bcl-xL (Kharbanda, Saxena et al. 2000; 
Upreti, Galitovskaya et al. 2008). Thus, drug resistance observed in 
Sca-1 high cells is partially explainable by overexpression of Bcl-
xL. 
In summary, our NCC-S1M cells serve as a good gastric cancer 
cell line model for the identification of candidate cancer stem cell 
markers as well as for testing immunotherapeutics and, possibly, 
anti-metastasis agents. Sca-1 is identified as a potential cancer 
stem cell marker in metastatic derivatives of a murine gastric 
cancer cell line. Although the Sca-1 results may not explain all 
aggressive behavior of the NCC-S1M cells, it suggests that 
Interleukin 1 - JNK - Bcl-xL axis observed in Sca-1 signature 






GENAERAL DISCUSSION AND CONCLUSION 
Gastric cancer is the second most common cause of cancer death, 
but, in the scientific and pharmaceutical communities, there are no 
genetically defined, murine metastatic gastric cancer models that 
closely recapitulate human gastric cancer. Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice described in this study are 
unique in several aspects. Gastric adenocarcinomas formed in these 
mice are of the mucus-secreting gastric epithelial cell origin, which 
is relevant for human gastric adenocarcinomas. In addition, tumor 
suppressor genes most commonly inactivated in human diffuse-
type gastric adenocarcinomas were targeted to be knocked-out in 
the gastroduodenal epithelium of this model. In this regard, our 
mouse gastric cancer cells of glandular origin uniquely recapitulate 
human gastric adenocarcinomas in genetic composition.  
The specific role of E-cadherin loss in the development of 
diffuse-type gastric adenocarcinomas was clearly documented by 
this cross-tissue tumorigenesis study. We demonstrate that loss of 
expression of E-cadherin occurs only in the gastric cancer model 
with the Cdh1 heterozygote and is a similar phenomenon that occurs 
in the human disease. This finding has not previously been 
demonstrated in a genetically-engineered mouse model system. 
CDH1 promoter hypermethylation is the most common cause of the 
second hit in human gastric cancer that develop in germline CDH1 




et al. reported that 4 of 6 human diffuse-type gastric carcinoma  
(HDGC) patients had promoter hypermethylation but the other two 
patients did not (Concolino, Papa et al. 2004). Thus, molecular 
mechanisms other than promoter hypermethyation, such as 
transcription factor mediated events, may play a role in CDH1 
down-regulation in HDGC. According to current data, CDH1 
promoter hypermethylation is detectable in about 50% of HDGC 
cases and in 40-80% of sporadic diffuse gastric cancer cases. 
Promoter methylation has been described in association with aging. 
While CDH1 somatic mutation and promoter hypermethyation is also 
frequent in sporadic diffuse-type gastric cancers, early onset 
gastric cancers are known to have relatively few methylation events 
for common tumor suppressors such as MLH1 (Carvalho, Milne et 
al. 2004). Our mouse models, which develop gastric cancer without 
carcinogen exposure, therefore, are relevant to human gastric 
cancer despite the low incidence of CDH1 promoter 
hypermethylation. Loss of expression of E-cadhein in the Cdh1 F/+ 
background appears to be a required, selected molecular change 
that is needed for both the human and mouse tumor formation. 
Studies are ongoing in our laboratory to identify gastric tissue-
specific epigenetic events or signaling pathway activation leading to 
E-cadherin loss that may be promoted by loss of Smad4 or p53. 
While Smad4 is inactivated in 40% of human gastric cancers 




progression have not been fully evaluated using in vivo models. 
Especially, the anti-metastatic role of Smad4 in gastric cancer, 
which has not been previously demonstrated in vivo. Our study is 
the first to demonstrate the Smad4 loss-induced β-catenin 
activation in gastric cancer, and is consistent with a prior report 
that Smad4 mediates canonical BMP signaling by repressing the 
transcription of β-catenin in SW480 colon cancer cells (Oliveira, 
Sousa et al. 2009). Therefore, inhibition of β-catenin may be a 
converging node for the anti-metastatic signaling pathways driven 
by E-cadherin and Smad4 in Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ mice.  
CSCs are promising for the development of anticancer drugs 
because it could explain resistance to chemotheraphy and eventual 
tumor relapse. The existence of a CSC in gastric cancer has been 
investigated in several reports, but robust CSC markers have not 
been identified in human and mouse gastric cancers. Sca-1 was 
overexpressed in metastatic NCC-S1M cells that demonstrate 
cancer stem cell-like features such as increased tumorigenicity, 
metastasis, and chemoresistance. High Sca-1 expression is 
associated with enhanced tumorigenicity or metastasis in breast or 
prostate cancers but not in gastrointestinal cancers (Cohn, 
Kramerov et al. 1997; Treister, Sagi-Assif et al. 1998; Witz 2000; 
Li, Welm et al. 2003; Xin, Lawson et al. 2005; Grange, Lanzardo et 




identify Sca-1 as an enrichment marker for tumor-initiating and 
chemoresistant population of gastric cancers. Sca-1 gene 
expression signature identified in our mouse tumor cells clustered 
pretreatment biopsy samples of patients according to their survival 
durations after cisplatin/fluorouracil chemotherapy. To our 
knowledge, our study is the first to demonstrate that Sca-1 is an 
enrichment marker for chemoresistance. 
Our study revealed the activation of the interleukin-1 receptor 
signaling in Sca-1 high gastric cancer cells. Activation of 
interleukin-1 receptor signaling pathway has been associated with 
aggressive tumor phenotypes such as growth, invasion, and 
metastasis in several types of mouse or human cancers(Gemma, 
Takenaka et al. 2001; Elaraj, Weinreich et al. 2006; Germano, 
Allavena et al. 2008). Especially, Bcl-xL over-expressed in Sca-1 
high cells. Bcl-xL confers resistance to multiple chemotherapy 
agent (Minn, Rudin et al. 1995) and multiple kinases, including JNKs, 
mediate phosphorylation of Bcl-xL (Kharbanda, Saxena et al. 2000; 
Upreti, Galitovskaya et al. 2008). Our data is consistent with these 
data in the literature, and further studies need to be performed to 
evaluate whether and how cancer stem cell phenotypes of Sca-1 
high cells are attributable to each of these components of 
interleukin-1 receptor signaling pathway.  
This long-term in vivo experiment evaluated the effect of loss of 




Smad4, on the development and metastasis of diffuse type gastric 
carcinoma in mice. By creating genetically-engineered mouse 
models closely recapitulating the mutation profiles in humans, we 
demonstrated the critical role of E-cadherin loss in the 
development of diffuse type gastric adenocarcinomas by cross-
tissue tumorigenesis study. Moreover, the metastatic phenotype of 
our mutant mice provides us a unique opportunity to dissect the 
roles of E-cadherin and Smad4 in gastric cancer progression, and 
in relation to EMT. We also demonstrated that the loss of E-
cadherin and Smad4 expression cooperate to promote lung 
metastasis through accumulating nuclear β-catenin. Taken 
together, our unique and novel murine gastric cancer models would 
be important to clarify the mechanism underlying HDGC formation 
and metastasis. It is also an excellent model for preclinical studies 
given its similarities with HDGC and its metastatic propensity. In 
addition, gene expression profiles of these models would facilitate 
the identification of putative gastric cancer stem cell markers as 







암  생  이에  E-cadherin, Smad4, 
그리고 p53  역할 
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E-cadherin (Cdh1), Smad4 그리고 p53  능 상실  암 
생에  요한 역할  하는 것  알  있다. 우리는 암, 장암, 
그리고 암에    자  역할  하고 하  해  
Pdx-1-Cre, Villin-Cre, 그리고 MMTV-Cre  자 삽입 마우스를 
이용하여 장    상피 포 특이  이  자를 
불 시킨 마우스를 작하 다. Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스에  Pdx-1-
Cre;Smad4F/F;Trp53F/F 마우스보다 암이 훨씬 높  도  
생하는 것이 인 었다 [P<0.001]. Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스에  생한 암  E-





Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스  장과 에  생한 
암에 는 E-cadherin 이 찰 었 며, 야생  Cdh1  
자를 가지고 있는 마우스  종양 생에  차이를 보이지 않았다. 
Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스에  Pdx-1-
Cre;F/F;Trp53 F/F;Cdh1F/F  마우스보다  빨리 암이 생하 는데, 
이는 Cdh1 이 합이 Smad4  p53이 불  상태에  암  
생과 진행  진한다는 것  보여 다. Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스  14.2%에  폐  이가 
찰 었 며, 다른 자 에 는  찰 지 않았다. Pdx-1-
Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스에  생한 암  칩습 인 
장  보이는 부 에  핵 내 β-catenin  축 이 찰 었다.  
이  같  상  E-cadherin  Smad4가 상인 마우스에   
찰 었 며, 이는 E-cadherin  Smad4에 한 β-catenin  
신  체계  억 가 Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 
마우스에  특이  찰  폐  이에   있  
보여 다. Pdx-1-Cre;Smad4F/F;Trp53F/F;Cdh1F/+  마우스에  생한 
암  부  립  포주들  β-catenin   감소시  
,  있게 포주들  이동 능 이 감소하는 것  인하 다. 
결국, 이  같  결과는 E-cadherin 과 Smad4  손실  p53  
손실과 함께 암  생과 이 과  진하는데 동한다는 것  
보여 다. 
또한 우리는 Villin-Cre;Smad4F/F;Trp53F/F;Cdh1F/+ 마우스에  
생한 암 부  마우스 암 포주를 립하 고, NCC-




주사하여 만들어진 종양 조직 부  폐  이 어  이소에  
이 이 향상  포주를 립하 다. 이 포주를 NCC-S1M  
명명하 다. 이 포주를  내 주사하   일  있게 종양  
하 고 NCC-S1 에 해 마우스에  향상  이 능  
보여주었 며, 상피 포에  간질 포  변이가 찰 었다. NCC-
S1M  종양   능   항암 에 한 항  포함하여 다양한 
암 포  특징  보여주었다. 미롭게도, NCC-S1 에 해  
NCC-S1M 에 는 Sca-1  과 이 찰 었다. Sca-1 양  종양 
포들  Sca-1  종양 포들에 해 마우스에  종양  하는 
능   항암 에 한 항 이 높  인할  있었다. Sca-1 양  
종양 포들  Sca-1  종양 포들에 해 interleukin 1 신  
달 경  가 찰 었다. 또한 Sca-1 양  종양 포들에  
Sca-1  포들에 해 증가한 자들  이용하여 123 명  
이  암 소견  보이는 자들  cisplatin 과 fluorouracil 료 후 
인 생존 시간에 라 단  지   있  인하 다. 결국, 
우리는 이 이 이 보  새 운 마우스 암 포주 모델  이용하여 
마우스 암  포  Sca-1  굴하 다. 
---------------------------------------- 
핵심어: E-cadherin, Smad4, p53, β-catenin, Sca-1, 암 포, 
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